



WE PERSEVERE



FACTOR
Osteosarcoma Conference
Salt Lake City | June 26-28, 2025

WELCOME FROM ANN GRAHAM

EXECUTIVE DIRECTOR, FOUNDER, OSTEOWARRIOR
MIB AGENTS OSTEOSARCOMA ALLIANCE

Dear Agent,

At our inaugural conference in 2017, I shared the poet, Alice Walker's profound words, "We are the ones we have been waiting for." Now, at our 8th conference, with many faces familiar from that very first gathering — and after years of relentless research, countless families served, and too many deeply missed OsteoAngels — we believe "**We Persevere**" is our most fitting theme for FACTOR 2025.



We gather again, truly empowered by perseverance. The journey through osteosarcoma, whether as a patient, a family member, a researcher, or a clinician, demands incredible strength and an unwavering spirit. At MIB Agents, our very purpose is to channel that collective determination, driving forward to Make It Better for every child facing this aggressive bone cancer. It's a continuous pursuit, fueled by our greater osteosarcoma community's resilience, knowledge, and an unbreakable belief in brighter outcomes.

Every grant pursued, every OsteoBites webinar shared, and every OS Navigation Packet provided is an act of this shared perseverance. It's the constant dedication of our Family Funds, the tireless work of our Junior Advisory Board and NextGen young adult members, and the collaborative spirit of experts worldwide. Your presence here is a testament to that collective strength. We are deeply grateful for your perseverance and unwavering support. Thank you for joining us in this vital mission, for being a part of our dedicated community, and for bringing your own spirit of perseverance to find better treatments and a cure for osteosarcoma. We need, and are deeply grateful for, YOU.

Welcome to your MIB FACTOR Conference, presented by SERB. **Let us persevere in Making It Better together.**

With Hope,

A handwritten signature in blue ink that reads "Ann".

CONTENTS

02	24	52	64
WELCOME FROM ANN GRAHAM	KEY PRESENTERS	BOARD OF DIRECTORS	FAMILY FUND ADVISORY COUNCIL
04	32	53	65
CONFERENCE NOTES	FACTOR 2024	SCIENTIFIC ADVISORY BOARD	FACTOR TRAVEL AWARDS
06	34	54	67
ABOUT MIB AGENTS	KEY PRESENTERS	JUNIOR ADVISORY BOARD	FACTOR VOLUNTEER AGENTS
06	46	61	67
ABOUT OUR PROGRAMS	OUTSMARTING OSTEOSARCOMA 2025	ABOUT MIB AGENTS FAMILY FUNDS	VENDOR PARTNERS
08	48	62	
MAP	HONORING THE FAMILY FUNDS POWERING OUTSMARTING OSTEOSARCOMA	MIB AGENTS FAMILY FUNDS	
10	50		
AGENDA	SENIOR LEADERSHIP TEAM		
19			
OSTEOWARRIOR HEADQUARTERS			
20			
POSTER SESSION			
22			
WELLNESS TRACK			

CONFERENCE NOTES

TIMELINE

Our timeline is extremely tight. Kindly arrive a few minutes before the session start time to ensure the meeting can begin and end promptly.

ETIQUETTE

Kindly refrain from requesting medical advice or to review a specific case in this venue.

NAME BADGES

Please visibly display your badge throughout the conference.

ELECTRONICS

Turn off or silence cell phones, PDAs, and electronic devices before each session begins.

PHOTOGRAPHY + VIDEO RECORDINGS

The conference will be photographed and video recorded. Images may be used in MIB Agents promotional materials.



Making
it better,
together.

Bone Sarcoma Program offers:

- Compassionate multidisciplinary cancer care
- Complex limb salvage surgeries
- Proton radiation therapy
- Access to cutting-edge clinical trials and research programs



Intermountain
Children's Health



HEALTH
UNIVERSITY OF UTAH

Childhood, Adolescent and
Young Adult Cancer

CHECK OUT

If you plan on checking out on Saturday, please do so in the morning and store your luggage with the Bell Captain. This will avert any delay in your departure plans and avoid any late-check out fees.

COVID OR OTHER ILLNESS

It is of the utmost importance that we keep each other safe at the MIB FACTOR Conference. If you are having symptoms including those associated with a cold or flu, we ask that you not attend - even if your test is negative.

GLOSSARY



HOW DO I ASK A QUESTION?



SUBMIT A QUESTION ONLINE VIA SLIDO

1. Scan the QR code
2. Select the "room" for the relevant panel
3. Type in your question

EVENT URL

[https://app.sli.do/
event/9U6rwKgMgnxrhr6fURFBA](https://app.sli.do/event/9U6rwKgMgnxrhr6fURFBA)

SLIDO EVENT CODE

#2762825



ASK A QUESTION IN PERSON

If you'd like to ask your questions directly, please raise your hand for **Kyle Okimoto** to bring the microphone to you. During the session please be specific and brief.

ABOUT MIB AGENTS

MISSION


MIB Agents is a leading pediatric osteosarcoma nonprofit dedicated to Making It Better for our community of patients, families, medical professionals, researchers, and industry partners through programs, education, and research.

VISION

A world with less toxic, more effective treatments and a cure for osteosarcoma.

VALUES

We are devoted to creating and instilling hope with and for our inclusive and collaborative osteosarcoma community. We do this through mutual trust, transparency, and compassion.



Original artwork by Gillian Bomi Okimoto, OsteoWarrior

ABOUT OUR PROGRAMS

PATIENT PROGRAMS

Ambassador Agents Connects osteosarcoma patients and families to trained osteosarcoma survivors and their families for mentorship and support.

Gamer Agents Lead Gamer Agents are trained to game with warriors in active treatment, connecting a community of OsteoWarriors and siblings.

Healing Hearts Offering a safe haven of love and comfort for grieving osteosarcoma families.

MIB Agents Family Funds In honor and memory of their children, Family Funds raise money to Make It Better for kids and young adults with osteosarcoma.

Prayer Agents Prayer Agents lift OsteoWarriors, OsteoAngels, and their families with prayers and intentions on the first Sunday of each month.

Secret Agent Missions Providing an experience or an item of comfort for OsteoWarriors in hospice.

Warrior Mail OsteoWarriors receive monthly letters of hope and cheer from MIB Agent Writers around the world.

EDUCATION

Osteosarcoma Handbook Written by osteosarcoma families and edited by leading physicians, *Osteosarcoma: From our Families to Yours* is a comprehensive guide to OS. Available in English, Spanish, and Mandarin.

OS Navigation Packets OS Navigation Packets include a hard copy of the OS Handbook, along with a wealth of helpful information and resources in both English and Spanish from our partners.

Connective Issue Monthly Newsletter A monthly roundup of all things osteosarcoma, including recent papers, open clinical trials, spotlight moments with OS people & labs -delivered straight to your inbox.

FACTOR Osteosarcoma Conference Since 2017, the annual MIB Agents FACTOR conference has united leading researchers, clinicians, and the osteosarcoma community—including patients, families, and survivors—to drive collaboration, advance treatments, and improve outcomes. FACTOR stands for Funding, Awareness, Collaboration, Trials, Osteosarcoma, and Research.

osTEAo AYA Podcast A podcast by OsteoWarriors who "spill the tea" on living with cancer as a young adult.

OsteoBites Webinar & Podcast – A weekly webinar series featuring the leaders in osteosarcoma research and other topics of interest to the osteosarcoma community.

Testing & Research Directory A guide to testing and research options to either help inform a personal treatment plan and/or contribute to general osteosarcoma research.

TURBO Virtual Tumor Board A bi-monthly virtual tumor review board for osteosarcoma open to global clinicians and researchers, TURBO provides an educational forum and fosters collaboration.

RESEARCH


Canine Trial Resources Connects the osteosarcoma community to canine clinical trial information and collaborative research opportunities.

Clinical Trial Search through ONTEX (Osteosarcoma Now Trial Explorer) A curated international database that explains osteosarcoma clinical trials, including their purpose and participation details.

Funding Opportunities Resource A resource hub for osteosarcoma researchers seeking grant and funding opportunities.

CURE-OS An international working group dedicated to advancing osteosarcoma single-cell research toward improving the care of OS patients.

OutSmarting Osteosarcoma Research Grants Since 2017, MIB Agents has supported 32 investigators and awarded \$2.5 million in research funding with our OutSmarting Osteosarcoma grant program.



FIRST FLOOR

Registration (Thursday – Saturday)

Welcome Reception (Thursday)

Speaker Dinner (Thursday)

General Session Room

Breakfast & Lunch (Friday & Saturday)

CURE-OS Working Group (Friday)

Poster Session (Friday)

HQ & Flower Room

Osteoasis Lounge

FACTOR Dinner & Formal

REGISTRATION AREA

GRAND SALON

LAUREL BRASSERIE & BAR

GRAND BALLROOM A & D

GRAND SALON

ENVY


GRAND BALLROOM RECEPTION A

OAK ROOM

EARL'S LOUNGE

CENTER COURTYARD

The
GRAND
AMERICA
Hotel



THIRD FLOOR

Wellness Room #1

Wellness Room #2

SARC YI Mentorship & Coaching (Friday)

Healing Hearts/Reflection Room for OsteoAngel Families

VIENNA

SUSSEX

VIENNA

PROVENCE

AGENDA

THURSDAY
JUN 26

4:30 pm - 5:30 pm	FACTOR Family Welcome Reception Hosted by Family Funds Grand Salon
5:30 pm - 6:30 pm	Welcome Reception / Docs vs. Warriors Challenge Grand Salon
6:45 pm - 9:00 pm	Speaker Dinner Laurel Brasserie & Bar
7:00 pm - 9:00 pm	FACTOR Community Dinner Lucky H Buffet at the Little America Hotel

WE PERSEVERE



HEALING HEARTS GRIEF RETREAT FOR BEREAVED PARENTS OF OSTEOANGELS

Lori Krause, Grief Coach, Hand Holders LLC

Don't hesitate to join Lori and your peers in a place to heal, strengthen your heart in community, feel cared for, inspired, and connected. There will be Healing Hearts veterans, as well as parents like you, who have not felt ready to join in until now.

We hope that you will take the opportunity to better understand your grief journey, enhance your coping skills, and reflect, renew and connect with others through the shared experience of living with the loss of a child from osteosarcoma. Please bring a printed photo of your child and a small object that reminds you of them.

This year's Retreat will take place in two 90 minute sessions:

Friday, June 27th, 10:45 am - 12:15 pm, and
Saturday, June 28th 3:00 pm - 4:30 pm

Lori Krause is a life coach with a focus on grief as well as end of life. A hospice-trained grief facilitator for both adults and children, Lori is an INELDA-trained End of Life Doula and has her professional coaching credential (PCC) with the ICF as an End of Life and Grief Coach. Lori's approach is to "hold hands" and walk alongside her clients as they process life's deep emotions, loss, and challenges. She creates a compassionate and supportive space by providing education on what is to be expected in grief and mourning, helping clients discover coping tools and new perspectives, and creating hope for the future. MIB Agents is fortunate to have Lori leading our Healing Hearts group sessions and workshops.

FRIDAY
JUN 27

All General Session Panels will be in
Grand Ballroom A&D unless otherwise noted.

7:00 am - 7:45 am	Breakfast Grand Salon
8:00 am - 8:10 am	Panel 1: MIB Panel Welcome Ann Graham MIB Agents Matteo Trucco, MD <i>Cleveland Clinic, MIB Agents Scientific Advisory Board</i>
8:10 am - 8:20 am	Opening Keynote Samantha Ulloa <i>MIB Agents Junior Advisory Board Member</i>
8:20 am - 8:28 am	Events / Fundraisers Anita Caldera <i>MIB Agents</i>
8:28 am - 8:36 am	Patient Programs Isabel Wolf <i>MIB Agents</i>
8:36 am - 8:44 am	Family Funds Bronwen Greene <i>MIB Agents Family Fund Advisory Council</i>
8:44 am - 8:52 am	Junior Advisory Board Kara Skrubis <i>MIB Agents</i>
8:52 am - 9:00 am	Scientific Programs Christina Ip-Toma <i>MIB Agents</i>
9:00 am - 9:10 am	Q&A
9:10 am - 9:20 am	Panel 2: Biological Drivers Of Osteosarcoma Introduction Ryan Kennington <i>MIB Agents Junior Advisory Board Member, Alumnus</i>
9:20 am - 9:30 am	Moderator Joshua Schiffman, MD <i>University of Utah, Huntsman Cancer Institute</i>
9:30 am - 9:40 am	Dissecting the developmental origins of osteosarcoma James Morrow, MD, PhD <i>Dana-Farber Cancer Institute</i>
9:40 am - 9:50 am	Heterogeneous and ongoing genomic rearrangements in a murine osteosarcoma model parallel human disease Mathieu Epinette, BS <i>Koch Institute for Integrative Cancer Research at MIT</i>
9:50 am - 10:00 am	Sensory neurons regulate osteosarcoma disease progression Sowmya Ramesh, PhD <i>Johns Hopkins University</i>
10:00 am - 10:10 am	Characterization of the anchor cell in preclinical models of metastatic osteosarcoma Kelly Gutpell, MBBCh, PhD <i>Nationwide Children's Hospital</i>
10:10 am - 10:30 am	Epigenetics and osteosarcoma oncogenesis Kevin Jones, MD <i>University of Utah, Huntsman Cancer Institute</i>
10:30 am - 10:45 am	Panel Discussion, Q&A
10:45 am - 12:15 pm	Healing Hearts for Parents Retreat Provence Lori Krause, Grief Coach <i>Hand Holders LLC</i>

AGENDA

FRIDAY
JUN 27

	Panel 3: Collaborative Data Ecosystems
10:45 am - 10:55 am	Introduction Inaaya Shariq MIB Agents Junior Advisory Board Member
	Moderator Sam Volchenboum, MD, PhD University of Chicago
10:55 am - 11:05 am	ICONIC: Improving outcomes through collaboration in osteosarcoma Sandra Strauss, MD, PhD UCL Cancer Institute
11:05 am - 11:15 am	Directly engaging participants in rare cancer research is feasible: The Osteosarcoma Project Katie Janeway, MD, MMSc Dana-Farber Cancer Institute
11:15 am - 11:25 am	FOSTER (Fight OsteoSarcoma Through European Research) Consortium Emanuela Palmerini, MD, PhD Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami
11:25 am - 11:35 am	Collaborative data ecosystems in mainland China Lu Xie, MD Peking University People's Hospital
11:35 am - 11:45 am	Pediatric Bespoke Therapeutic Discovery Workshop on Osteosarcoma - Community Priorities David Jenkinson, PhD LifeArc
11:45 am - 11:55 am	BTC Osteosarcoma TeamLab John BA Okello, PhD, MBA Break Through Cancer
11:55 am - 12:15 pm	Panel Discussion, Q&A
12:15 pm - 12:30 pm	OutSmarting Osteosarcoma 2025 Hero Awards Moderators Christina Ip-Toma MIB Agents Matteo Trucco, MD Cleveland Clinic
	A comparative approach to exploring fluorescence in situ hybridisation (FISH) biomarkers for advancing the diagnosis, prognostication and treatment of osteosarcoma Amy LeBlanc, DVM National Cancer Institute
	Implementing personalized, adaptive therapies in osteosarcoma Corey Weistuch, PhD Memorial Sloan Kettering Cancer Center
	Validation of MCL1 inhibition and combinatorial therapy for elimination of osteosarcoma lung metastasis Alexander Davies, DVM, PhD Oregon Health & Science University In partnership with Fishin' for the Cure, Because of Matthew
	High-throughput characterization of pathobiological responses in osteosarcoma tumors treated with LRRCT15-targeted radiotherapy to uncover curative co-treatment approaches David Ulmert, MD, PhD University of California, Los Angeles Because of Sydney
12:30 pm - 1:30 pm	Lunch Grand Salon
	Panel 4: Tumor Heterogeneity and Microenvironment Interactions
1:30 pm - 1:40 pm	Introduction Matthew Ceelen MIB Agents Junior Advisory Board Member
	Moderator Rosandra Kaplan, MD National Cancer Institute/National Institutes of Health

FRIDAY
JUN 27

All General Session Panels will be in
Grand Ballroom A&D unless otherwise noted.

1:40 pm - 1:50 pm	Dynamic tissue models reveal targetable mechanisms of single cell drug resistance in complex tumor ecosystems Alexander Davies, DVM, PhD Oregon Health & Science University
1:50 pm - 2:00 pm	3D patient avatars, cell therapy, and microscopic mayhem Greg Sawyer, PhD Moffitt Cancer Center
2:00 pm - 2:10 pm	Toward a greater understanding of shared molecular alterations in canine and human osteosarcoma: an update from the NCI DOG2 project Anjali Garg, PhD Center for Cancer Research, National Cancer Institute, National Institutes of Health
2:10 pm - 2:20 pm	Project OsteoCAR: Building a comprehensive resource for cell type annotation and transcriptomic exploration of osteosarcoma Yogesh Budhathoki, MS, PhD Candidate Nationwide Children's Hospital
2:20 pm - 2:30 pm	A comparative understanding of oncogenic MYC signaling in the osteosarcoma metastatic tumor immune microenvironment Rebecca Makii, MS, DVM, DACVP Colorado State University
2:30 pm - 2:50 pm	Panel Discussion, Q&A
2:50 pm - 3:05 pm	Break
3:05 pm - 4:25 pm	Breakout Session: SARC and Other Sarcoma mentorship and coaching for young investigators in sarcoma research (1 hour) Vienna

Discussion Leaders

Scott Okuno, MD | Mayo Clinic

Lara Davis, MD | Oregon Health & Science University

Kevin Jones, MD | University of Utah, Huntsman Cancer Institute

During this session, SARC panelists will discuss efforts to develop talent and mentor individuals who are interested in an academic career in sarcoma. Young Investigators will understand the sarcoma landscape of how to navigate and make connections within the sarcoma community, including the development of clinical trials, engagement of advocacy groups, CTEP sarcoma structure and basic science labs.

We will discuss:

- How to select mentors and mentorships
- Funding for these opportunities
- Support from local cancer centers

— or —

Breakout Session: CURE-OS Working Group: A blueprint for translating single-cell discoveries into better osteosarcoma treatments

Envoy

Discussion Leaders

Anand Patel, MD, PhD | St. Jude Children's Research Hospital

Corey Weistuch, PhD | Memorial Sloan Kettering Cancer Center

Dan Regan, DVM, PhD | Colorado State University

Emanuela Palmerini, MD, PhD | Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami

Jovana Pavicic, MD | Memorial Sloan Kettering Cancer Center

AGENDA

FRIDAY
JUN 27

Join us for an open forum on advancing single-cell research into clinical care for osteosarcoma patients. As part of the international CURE-OS working group, we will review evolving recommendations on using single-cell technologies to study intra-tumoral heterogeneity (ITH) and the tumor microenvironment (TME) and discuss strategies for translating these insights into personalized treatments.

Topics include:

- Key components of osteosarcoma tumors and their implications for treatment
- Maximizing the impact of future research studies
- Overcoming barriers to clinical implementation

This interactive session is open to all and aims to foster collaboration, refine research priorities, and accelerate progress in the treatment of osteosarcoma.

— or —

Shelter Me

Screening of Shelter Me | The Cancer Pioneers:

PBS documentary on comparative oncology

Grand Ballroom AD

Presented by Steven Latham

A feature documentary about groundbreaking clinical trials for dogs with cancer and how these treatments are being applied to people with cancer, this film features some of the leading scientists at the NCI/NIH, the University of Pennsylvania, the University of Illinois, the University of Wisconsin and Colorado State University. Film producer Steven Latham will introduce the film and be available for Q&A afterwards.

Please see the Wellness Agenda for two additional session options during this time.

4:25 pm - 4:35 pm **Break**

4:35 pm - 5:00 pm **OutSmarting Osteosarcoma 2025 Hope Young Investigator Awards**
Moderators

Christina Ip-Toma | MIB Agents

Matteo Trucco, MD | Cleveland Clinic

Extracellular matrix degradation to overcome osteosarcoma chemoresistance
Ram Rao, MD, PhD | Seattle Children's Hospital

Identifying mechanisms of chemoresistance in metastatic osteosarcoma using molecular barcoding
Aafrin M. Pettiwala, PhD | University of California, San Francisco

Targeting EPHA2 with dual-armored CAR T cells for immunotherapy in pediatric osteosarcoma
Ali Cihan, PhD | Memorial Sloan Kettering Cancer Center
Because of Isaac

Synergy of ATM and PARP inhibitors in pediatric osteosarcoma
Janeala Morsby, PhD | St. Jude Children's Research Hospital
Because of Buddy

Next generation dual-CAR gamma delta T cells for the treatment of pediatric osteosarcoma
Joseph Skeate, PhD | University of Minnesota
Because of Annaleigh

Oncogenic structural variation in the genome of pediatric osteosarcoma
Andrew S. Clugston, PhD | University of California, San Francisco
In partnership with the RISE Foundation, Because of Reese

FRIDAY
JUN 27

5:00 pm - 5:45 pm **Poster Session**
Grand Ballroom Reception A.

6:30 pm - 7:00 pm **Group Photo**
Center Courtyard

7:00 pm - 8:30 pm **Dinner**
Center Courtyard

8:30 pm - 10:00 pm **FACTOR Formal**
Center Courtyard

All General Session Panels will be in
Grand Ballroom A&D unless otherwise noted.

WE PERSEVERE

SANOFI IS COMMITTED TO
INNOVATION IN FIGHTING CANCER

LET'S
Future



FOLLOW US
TO THE FUTURE
OF ONCOLOGY

sanofi

© 2024 sanofi-aventis U.S. LLC. All Rights Reserved. Sanofi is a registered trademark of Sanofi or an affiliate. MAT-US-2401824-v1.0-02/2024

Y-mAbs
Therapeutics is
Proud to Support
MIB Agents and the
FACTOR Conference

 **Y-mAbs**
Therapeutics, Inc.

AGENDA

SATURDAY
JUN 28

7:00 am - 7:45 am	Breakfast Grand Salon
8:00 am - 8:10 am	Panel 5: Mechanisms of Resistance and Evolution Introduction Sona Kocinsky, <i>MIB Agents Junior Advisory Board Member</i>
	Moderator Robert Gatenby, MD <i>H. Lee Moffitt Cancer Center</i>
8:10 am - 8:20 am	Molecularly-driven information on patient-derived xenografts (PDX) and cell lines leads to ixabepilone repurposing for resistant osteosarcoma Katia Scotlandi, PhD <i>IRCCS Istituto Ortopedico Rizzoli</i>
8:20 am - 8:30 am	Inhibition of the mitochondrial oxidative stress response in metastatic osteosarcoma cells prevents growth in murine lung tissue Michael Lizardo, PhD <i>BC Cancer</i>
8:30 am - 8:40 am	Repurposing drugs for osteosarcoma Shahana Mahajan, PhD* <i>Hunter College, City University of New York</i>

8:30 am - 9:30 am	Count Me In Research Bee with Caregivers Sussex <i>Elana Anastasio and Taisha Hendrickson Broad Institute of MIT and Harvard</i> <i>An open forum to learn about and enroll in the CMI study to advance osteosarcoma research.</i>
-------------------	--

8:40 am - 8:50 am	Harnessing mutational signatures to pinpoint the development of chemoresistance in metastatic and relapsed osteosarcoma Sasha Blay, PhD Candidate <i>The Hospital for Sick Children</i>
8:50 am - 9:00 am	Understanding tumor evolution and mechanisms of resistance in osteosarcoma Chelsey Burke, MD* <i>Stanford University School of Medicine</i>
9:00 am - 9:20 am	Panel Discussion, Q&A
9:20 am - 9:35 am	Break
9:35 am - 9:45 am	Panel 6: Precision Medicine Introduction Alejandro Lopez <i>MIB Agents Junior Advisory Board Member</i>
	Moderator Alejandro Sweet-Cordero, MD <i>University of California, San Francisco</i>
9:45 am - 9:55 am	Clinical biomarkers for osteosarcoma stratification (cBOSS): Insights from an international working group Amanda Marinoff, MD <i>University of California, San Francisco</i>

9:45 am - 10:30 am	Count Me In Research Bee with JAB/HQ OsteoWarriors 18+ Sussex <i>Elana Anastasio and Taisha Hendrickson Broad Institute of MIT and Harvard</i> <i>An open forum to learn about and enroll in the CMI study to advance osteosarcoma research.</i>
--------------------	--

SATURDAY
JUN 28

9:55 am - 10:05 am	Prospective evaluation of ctDNA among patients with localized osteosarcoma identifies patients at high-risk of disease relapse: A report from the LEOPARD study David Shulman, MD Dana-Farber Cancer Institute
10:05 am - 10:15 am	Correlative studies from NPCF Phase II trial of gemcitabine and nab-paclitaxel for recurrent osteosarcoma Masanori Hayashi, MD University of Colorado
10:15 am - 10:25 am	Prognostic and mifamurtide-related signatures for localized osteosarcoma: an ISG/OS2 trial correlative study of tumor immune microenvironment (TME) Emanuela Palmerini, MD, PhD Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami
10:25 am - 10:35 am	Prognostic significance and microenvironment influence of cMYC in osteosarcoma Matthew Dietz, DO, MSEd University of Utah/Primary Children's Hospital
10:35 am - 10:55 am	Panel Discussion, Q&A
10:55 am - 11:10 am	Break
	Panel 7: Patient Panel
11:10 am - 11:20 am	Introduction Mackenzie Maddry MIB Agents Junior Advisory Board Member
	Moderator Kurt R. Weiss, MD University of Pittsburgh and UPMC Hillman Cancer Center
11:20 am - 12:30 pm	MIB Agents Junior Advisory Board Panelists Andrew Bisaga Elise Robinson Mackenzie Maddry Matthew Ceelen Sona Kocinsky
12:30 pm - 1:30 pm	Lunch Grand Salon
	Panel 8: Integrative Approaches to Advancing Osteosarcoma Immunotherapies
1:30 pm - 1:40 pm	Introduction Sebastian Wang MIB Agents Junior Advisory Board Member
	Moderator Eugenie Kleinerman, MD UT MD Anderson Cancer Center
1:40 pm - 1:50 pm	Defining the immunopeptidome of osteosarcoma nominates candidate therapeutic targets Richa Kapoor, PhD Children's Hospital of Philadelphia
1:50 pm - 2:00 pm	Evasion of endogenous CD8 T-cell responses in murine osteosarcoma Geoffrey Smith, MD, PhD Boston Children's Hospital / Dana-Farber Cancer Institute and Massachusetts Institute of Technology
2:00 pm - 2:10 pm	cGAS-STING drives immune evasion in osteosarcoma and is therapeutically targetable via STING agonism Betsy Young, MD* UCSF Benioff Children's Hospitals
2:10 pm - 2:20 pm	Surface and global proteome profiling identifies ROR2 as an actionable immunotherapeutic target in osteosarcoma Brian Mooney, PhD BC Cancer Research Centre

AGENDA

SATURDAY
JUN 28

All General Session Panels will be in
Grand Ballroom A&D unless otherwise noted.

2:20 pm - 2:30 pm **Repurposing virus specific T cells as immune therapy for osteosarcoma**
Arianexys Aquino-Lopez, MD, PhD* | Baylor College of Medicine

2:30 pm - 2:50 pm **Panel Discussion, Q&A**

3:00 pm - 4:30 pm **Healing Hearts for Parents Retreat**
in Provence
Lori Krause, Grief Coach / Hand Holders LLC

2:50 pm - 3:15 pm **Break**

Panel 9: Clinical Trials

3:15 pm - 3:25 pm **Introduction**
Andrew Bisaga | MIB Agents Junior Advisory Board Member

Moderator
Katie Albert, MD | Seattle Children's Hospital, University of Washington

3:25 pm - 3:35 pm **Focus on clinical implementation**
Alanna Church, MD | Boston Children's Hospital & Dana-Farber Cancer Institute

3:35 pm - 3:45 pm **Crucial collaborations: Key for success of pediatric oncology clinic trials**
Brenda Weigel, MSc, MD | St. Jude Children's Research Hospital

3:45 pm - 3:55 pm **Osteosarcoma maintenance therapy with OST31-164 (OST-164-01) - Primary results**
Damon Reed, MD | Memorial Sloan Kettering Cancer Center

3:55 pm - 4:05 pm **Targeting TCF-beta signaling in the tumor microenvironment as an effective therapy in osteosarcoma**
Kristen VanHeyst, DO | University Hospitals/Rainbow Babies and Children's Hospital

4:05 pm - 4:15 pm **RNA PRIME - Harnessing tumor RNA for immunotherapy against osteosarcoma**
John A. Ligon, MD | University of Florida

4:15 pm - 4:35 pm **Panel Discussion, Q&A**

4:35 pm - 4:50 pm **Closing Remarks**
Ann Graham
Christina Ip-Toma
Matteo Trucco, MD

4:50 pm - 5:00 pm **Closing Keynote**
Walker Smallwood | MIB Agents Junior Advisory Board Member

WE PERSEVERE

OSTEOWARRIOR HEADQUARTERS

OsteoWarriors and Siblings ages 22 and under can attend HQ.

THURSDAY
JUN 26

3:00 pm - 7:00 pm	HQ Opens Oak Room
4:00 pm - 4:30 pm	HQ Welcome Meeting Oak Room
5:30 pm - 6:30 pm	Welcome Reception & Doctors vs Warriors Challenge Grand Salon
7:00 pm - 9:00 pm	FACTOR Community Dinner Lucky H Buffet at the Little America Hotel
9:00 pm - 11:00 pm	HQ Re-Opens Oak Room

FRIDAY
JUN 27

7:00 am - 7:45 am	Breakfast Grand Salon
8:00 am - 11:00 pm	HQ Opens Oak Room
9:00 am - 12:00 pm	F5RS Bunnies Oak Room
9:30 am - 10:30 am	Continental Breakfast Available Oak Room
12:30 pm - 1:30 pm	HQ Closes for Lunch Grand Salon
1:30 pm - 2:45 pm	NAC Team Building Activity Oak Room
3:00 pm - 6:00 pm	HQ Photoshoot Casual with Parents Oak Room
4:45 pm - 6:15 pm	HQ Hairdressers Oak Room
6:30 pm - 7:00 pm	FACTOR Group Photo Center Courtyard
7:00 pm - 10:00 pm	Dinner & FACTOR Formal Center Courtyard
10:00 pm - 11:00 pm	FACTOR Formal HQ After-Party Oak Room

SATURDAY
JUN 28

7:00 am - 7:45 am	Breakfast Grand Salon
8:00 am - 5:30 pm	HQ Opens Oak Room
8:00 am - 9:30 am	Shopping Trip Little America
9:30 am - 10:30 am	Continental Breakfast Available Oak Room
11:10 am - 12:30 pm	OsteoWarrior Patient Panel Grand Ballroom A & D
12:30 pm - 1:30 pm	HQ Closes for Lunch Grand Salon
1:30 pm - 2:45 pm	Intermountain Therapy Animals Oak Room
3:00 pm - 4:00 pm	Flower Arranging Oak Room
4:35 pm - 5:00 pm	Thank You, Closing Remarks & Closing Keynote Grand Ballroom A & D
5:00 pm - 5:30 pm	HQ Closes Oak Room



POSTER SESSION

1. Marta Roman Moreno, PhD
(presented by Alejandro Sweet-Cordero, MD)
University of California, San Francisco
Dissecting and Targeting Metastatic Drivers in Osteosarcoma
2. Eunice Lopez Fuentes, PhD
University of California, San Francisco
RUNX2 and FOSL1 Orchestrate Epigenetic Subtypes and Cellular Plasticity in Osteosarcoma
3. Pooja Rao, MS
Hunter College of CUNY jointly with Research Foundation of CUNY
Riluzole-Induced Radiosensitization of Osteosarcoma to Single High Dose Radiation Therapy
4. Marika Klosowski, DVM
Colorado State University
Fibroblast Activation Protein as an Immunotherapy Biomarker and CAR T-cell Target in the Osteosarcoma Tumor Microenvironment
5. Sagar Bhattacharya, PhD
University of California, San Francisco
De Novo Design of Protease-Activated Anticancer Proteins
6. Ayesha Qureshi, MD (presented by Tom Scharschmidt, MD)
The Research Institute at Nationwide Children's Hospital
Incidence, Associated Factors, and Proposed Classification of Wound Complications in Pediatric Extremity Bone Sarcomas following Extirpative Surgery
7. Maia Brown, MD candidate (presented by Kurt R. Weiss, MD)
University of Pittsburgh and UPMC Hillman Cancer Center
Investigating Macrophage Populations in Metastatic Sarcoma Samples
8. Tanya Heim, MS (presented by Kurt R. Weiss, MD)
University of Pittsburgh and UPMC Hillman Cancer Center
Disulfiram and Enzalutamide Combination Therapy to Treat Metastatic Osteosarcoma
9. Lu Xie, MD
Peking University People's Hospital
B7-H3 as a Prognostic Biomarker in Osteosarcoma: Insights into Clinical Outcomes
10. Lu Xie, MD
Peking University People's Hospital
Chemotherapy-Induced Thrombocytopenia in Patients With Primary Bone Sarcomas: Current Status and Approach to Management: A Large-Scale Real-World Analysis
11. Abena Peasah, MS
Stanford University
A Tissue-Engineered 3D Model for Deciphering the Role of Macrophages in Osteosarcoma Drug Responses and Biology
12. Jeehee Lee, PhD
Stanford University
Personalized Cancer Research: Bioengineered 3D Osteosarcoma Models to Investigate Tumor Heterogeneity and Drug Responses
13. Rocio Rivera-Valentin, MD, PhD
University of Puerto Rico Comprehensive Cancer Center
Epidemiology and Molecular Determinants of Pediatric Osteosarcoma in Underserved Populations
14. Busra Turgu, PhD, MSc
BC Cancer Center
Finding New Immunotherapy Targets in Osteosarcoma
15. Yanding Zhao, PhD
Stanford University
Distinct Patterns of Chromosomal Instability Fuel Osteosarcoma Progression and Influence Patient Outcomes



WE PERSEVE

GRAND BALLROOM AD - GENERAL SESSION ROOM



WELLNESS TRACK

FRIDAY
JUN 27

6:30 am - 7:15 am Vienna	Center, Stretch, Balance, Breathe with Leslie Peterson Begin your day with gentle stretching and mindful movement to awaken your body, center your mind, and cultivate calm. Mats, Blankets & Towels will be provided.
9:30 am - 10:30 am Vienna	Navigating Loss and Transition (For Families & Caregivers) with Lori Krause This workshop supports families and caregivers in exploring both death-related and "living losses"—grief that can arise from life changes such as the loss of identity, health, relationships, or future expectations.
9:30 am - 10:30 am Sussex	Nail Art with Elise Robinson Join Elise for fun and relaxing manicures, complete with creative nail art to brighten your day!
1:45 pm - 2:45 pm Grand Salon Patio	Salsa Dancing with Andrew Bisaga Join Andrew for a fun and beginner-friendly salsa class!
1:45 pm - 2:45 pm Oak Room	Flower Arranging with Tedd Kapinos Tedd is a fixture at FACTOR! Join him to help assemble the centerpieces for Friday evening's Dinner and Dance.
3:05 pm - 4:05 pm Sussex	Navigating Loss and Transition (For healthcare professionals and patients/caregivers) with Lori Krause This workshop guides professionals in understanding and processing both death-related and "living losses"—grief tied to life changes like shifts in identity, health, relationships, or careers.
3:15 pm - 4:15 pm Provence	Sound Bath with Raven Feurer Raven offers sound journeys that promote relaxation and emotional well-being. Mats, Blankets and Towels will be provided.



ANDREW BISAGA

OsteoWarrior, Ambassador Agent, and Junior Advisory Board Member, Andrew, loves to playing and building guitars during his free time.



ELISE ROBINSON

OsteoWarrior, Ambassador Agent, and Junior Advisory Board Member, Elise, is a multi-talented athlete, musician, Nursing Student and nail art enthusiast.



LESLIE PETERSON

Mom of OsteoAngel Brooke, MIB Family Fund Holder, Leslie, completed yoga teacher training to deepen her practice and share its benefits.



LORI KRAUSE

MIB Healing Hearts Facilitator, Owner of Hand-Holders.

SATURDAY
JUN 28

6:30 am - 7:00 am Meet in lobby	Morning Fun Run with Matteo Trucco Join Dr. Trucco for an early morning fun run in Salt Lake City!
6:30 am - 7:15 am Vienna	Center, Stretch, Balance, Breathe with Leslie Peterson Begin your day with gentle stretching and mindful movement to awaken your body, center your mind, and cultivate calm. Mats, blankets & towels will be provided.
9:45 am - 10:45 am Vienna	Let's Write Warrior Mail + Bunnies with Sassy Pickard Learn all about joining our highly successful and popular Warrior Mail Program. All supplies will be provided. Isabel and Sassy will give guidance and share a story or two!
1:45 pm - 2:45 pm Oak Room	Flower Arranging with Tedd Kapinos Learn design principles and techniques to create beautiful arrangements.
1:45 pm - 2:45 pm Sussex	Nail Art with Elise Robinson Join Elise for fun and relaxing manicures, complete with creative nail art to brighten your day!
3:15 pm - 4:15 pm Vienna	Sound Bath with Raven Feurer Raven offers sound journeys that promote relaxation and emotional well-being. Mats, blankets & towels will be provided.




MATTEO TRUCCO

MIB FACTOR Co-Chair, Member of the Board of Directors, Scientific Advisory Board, and Director of the Children's Cancer Innovative Therapy Program and the Pediatric Hematology/Oncology and Bone Marrow Transplant Department at Cleveland Clinic Children's



SASSY PICKARD

Devoted MIB Writer Agent, Writer Agent FB Manager, Founder of FSRS Bunny Rescue and Therapy Bunnies, assisted by Terri Cook.



RAVEN FEURER

Soul Connector & Certified Sound Facilitator, Shamanic Energy Practitioner



TEDD KAPINOS

Owner of Jasper & Prudence Floral Design, serving all of New England, as well as destination weddings and events.

KEY PRESENTERS



ALANNA CHURCH, MD

Boston Children's Hospital/Dana-Farber Cancer Institute



ALEJANDRO SWEET-CORDERO, MD

University of California, San Francisco



ALEXANDER DAVIES, DVM, PhD

Oregon Health & Science University

Focus on clinical implementation

Dr. Church is currently a Molecular and Pediatric Pathologist at Boston Children's Hospital, where she is a founder and associate medical director of the Laboratory for Molecular Pediatric Pathology (LaMPP). She is an Assistant Professor of Pathology at Harvard Medical School, the Program Director for the Harvard Molecular Genetic Pathology Fellowship, and the incoming Chair of Clinical Practice for the Association for Molecular Pathology. Her clinical and research work focuses on bringing molecular testing to the clinical care of children with cancer. Through institutional projects (the Profile study, GAIN consortium study), she has profiled thousands of children's tumors and has used these results to make real-time impacts on their diagnoses and treatments. She is involved in national initiatives to improve the quality and access to molecular testing for children with cancer, including the NCI-funded Count Me In Study (Dana Farber, Broad Institute), the National Comprehensive Cancer Network, the National Institutes of Health, and the Children's Oncology Group.

Moderator: Precision Medicine

I am a cancer biologist and practicing pediatric oncologist focused on basic and translational cancer research. Our sarcoma work is focused on defining mechanisms driving osteosarcoma and Ewing sarcoma progression, metastasis, and therapy resistance. We have extensive expertise in integrative genomic analysis (WGS, RNAseq, ATACseq) and functional genomic studies using CRISPR/CAS9 and lineage tracing studies. We use these tools to drive gene and network discovery applied to primary tumors, patient-derived xenograft models, and genetically engineered mouse models. I also have experience in real-world application of tumor sequencing for precision cancer medicine, and I currently lead the Molecular Oncology Initiative (MOI) at UCSF. Since June of 2022, I serve as division chief of pediatric oncology at Benioff Children's Hospitals (San Francisco and Oakland).

Dynamic tissue models reveal targetable mechanisms of single-cell drug resistance in complex tumor ecosystems

Dr. Alexander Davies graduated with a Ph.D. in Biochemistry and Molecular Biology and a D.V.M., with an interest in comparative oncology, from the University of California, Davis. He then completed a post-doctoral fellowship in cancer biology at Lawrence Berkeley National Laboratory before joining The Ohio State University as faculty in the Department of Veterinary Biosciences. While at OSU, he was a member of the Comprehensive Cancer Center and faculty in the Cancer Biology and Cancer Engineering programs. Currently, Dr. Davies is an Assistant Professor at the Knight Cancer Institute within the Division of Oncological Sciences and Cancer Early Detection Advanced Research Center (CEDAR), with a joint appointment in the Department of Pediatrics. His work focuses on dynamic tumor-microenvironment signaling cross-talk, signal integration, and the development of 3D organotypic and tissue models to study these interactions using advanced live-cell microscopy techniques.



AMANDA MARINOFF, MD

UCSF

Clinical biomarkers for osteosarcoma stratification (CBOSS): Insights from an international working group

Dr. Amanda Marinoff is a pediatric oncologist and translational researcher specializing in osteosarcoma. Her work focuses on integrating genomic profiling, biomarker discovery, and precision medicine approaches to improve risk stratification and treatment selection. She is particularly interested in developing clinically applicable biomarkers to enhance prognostic accuracy and guide personalized treatment strategies. In addition to biomarker research, Dr. Marinoff is actively involved in developmental therapeutics, working to bridge preclinical discoveries with early-phase clinical trials for relapsed and refractory sarcomas. She collaborates with both laboratory scientists and clinical researchers to advance novel therapeutic strategies and integrate molecularly informed approaches into clinical trial design. Dr. Marinoff trained at Harvard Medical School, Boston Children's Hospital, and UCSF, where she remains dedicated to translating genomic insights into improved outcomes for children, adolescents, and young adults with osteosarcoma.



ANAND PATEL, MD, PhD

St. Jude Children's Research Hospital

Moderator: CURE-OS Working Group: A blueprint for translating single cell discoveries into better osteosarcoma treatments

Dr. Patel is a pediatric oncologist who received his MD and PhD from the Mayo Clinic in Rochester, Minnesota. He completed internship and residency in general pediatrics at St. Louis Children's Hospital/Washington University in St. Louis, and clinical fellowship in Pediatric Hematology/Oncology at St. Jude Children's Research Hospital. In 2020, he was selected as a Damon Runyon Sohn-Pediatric Cancer Research fellow. He has been honored as an AACR NextGen Star, received the 2022 Damon Runyon Jake Wetchler Award for Pediatric Innovation, as well as an "Outside the Box" Grant from Rally Foundation for novel research ideas pertaining to rhabdomyosarcoma. Dr. Patel is interested in understanding the mechanisms driving recurrence in pediatric cancers, understanding the interplay between malignant cells and the tumor microenvironment, and building molecular tools to understand how malignant cells cooperatively interact with each other.



ANJALI GARG, PhD

Center for Cancer Research, National Cancer Institute, National Institutes of Health

Toward a greater understanding of shared molecular alterations in canine and human osteosarcoma: An update from the NCI DOG2 project

Dr. Anjali Garg is a computational biologist with expertise in multi-omics data analysis. Her research is focused on building the multiomics landscape of canine osteosarcoma. Dr. Garg's work aims to bridge the gap between canine and human osteosarcoma research and discover novel biomarkers and therapeutic approaches that can benefit both species.

KEY PRESENTERS



ARIANEXYS AQUINO LÓPEZ, MD, PhD

Baylor College of Medicine

Repurposing virus specific T-cells as immune therapy for osteosarcoma

Dr. Aquino López is currently an Instructor at the Texas Children's Hospital Cancer and Hematology Center. She completed her MD/PhD training through the NCI-funded US4 program, a partnership between The University of Texas MD Anderson Cancer Center, UTHealth Graduate School, and the University of Puerto Rico Medical School. Subsequently, she completed her Pediatrics and Hematology-Oncology training at Baylor College of Medicine. Witnessing her brother go through osteosarcoma treatment served as an inspiration for her to study ways to improve cancer therapies. Her interests include solid tumor immunotherapy and investigating approaches to potentiate anti-tumor effects of cell therapies against oncologic malignancies. She is also interested in studying the impact of tumor microenvironment on immune suppression to develop approaches to overcome cancer immune evasion.



BETSY YOUNG, MD

UCSF Benioff Children's Hospitals

cGAS-STING drives immune evasion in osteosarcoma and is therapeutically targetable via STING agonism

As a physician-scientist and a pediatric oncologist, I aim to advance the field of pediatric oncology in my research career focused on the immunobiology of osteosarcoma. I completed my Pediatric Hematology/Oncology fellowship training at UCSF, receiving strong clinical training in high-risk pediatric solid tumors and early-phase clinical trials. Now, as an Assistant Professor, I am investigating the pathogenesis of osteosarcoma metastasis in the Sweet-Cordero lab at UCSF, with a specific focus on immuno-oncology that is strengthened by my collaboration with faculty in UCSF's ImmunoX. My career goal is to become an independent physician-scientist with a focus on pediatric osteosarcoma immunobiology. Clinically, my area of expertise is pediatric sarcoma, and I am a member of the UCSF Pediatric Solid Tumor group. In my leisure time, I enjoy being outdoors, traveling, and spending time with my husband and son.



BRENDA WEIGEL, MSc, MD

St. Jude Children's Research Hospital

Crucial collaborations: Key for success of pediatric oncology clinic trials

Brenda Weigel, MSc., MD, is Vice President of Clinical Research Administration at St. Jude Children's Research Hospital, responsible for industry engagement. She previously was the Director of the Division of Pediatric Hematology/Oncology and a Professor cross-appointed at the University of Minnesota's Masonic Cancer Center and the Department of Pediatrics, and held the Lehman/Children's Cancer Research Fund Endowed Chair in Pediatric Cancer. She was the Co-Director of the Sarcoma Program for the Masonic Cancer Center. Dr. Weigel received her medical degree from McMaster University in Hamilton, Ontario, and completed her residency in pediatrics at the University of Western Ontario, followed by her fellowship in Pediatric Hematology/Oncology and Bone Marrow Transplant at the University of Minnesota. Dr. Weigel's major interests have been advancing new therapies for children with cancer. Her research interests are centered on her extensive involvement with the Children's Oncology Group (COG). She chaired the Developmental Therapeutics Committee and the NCI-funded Pediatric Early Phase Trials Network from 2013-2024. She is also active in the COG's Soft Tissue Sarcoma committee and led trials in rhabdomyosarcoma.

WE PERSEVERE



BRIAN MOONEY, PhD

BC Cancer Research Centre

Surface and global proteome profiling identifies ROR2 as an actionable immunotherapeutic target in osteosarcoma

Dr. Mooney received his BSc in Biochemistry from University College Dublin in 2013 and then went on to complete his PhD under the supervision of Dr. Darran O'Connor at the Royal College of Surgeons in Ireland. His PhD work, supported by an Irish Cancer Society research scholarship, was primarily focused on understanding mechanisms of anti-endocrine drug resistance in breast cancer and was awarded in 2018. Since 2020, Dr. Mooney has worked as a research fellow under the supervision of Dr. Gregg Morin and Dr. Poul Sorensen at the BC Cancer Research Institute in Vancouver, Canada. He is primarily interested in identifying and translating surface proteins with immunotherapeutic potential in pediatric cancers. Dr. Mooney has held a Michael Smith Health Research BC Research fellowship for identifying actionable immunotherapy targets in osteosarcoma, with a particular emphasis on surface proteins involved in metastasis.



CHELSEY BURKE, MD

Stanford University School of Medicine

Understanding tumor evolution and mechanisms of resistance in osteosarcoma

Dr. Chelsey Burke is a pediatric oncologist at Stanford University. She obtained her medical degree from St. George's University and, after completing pediatric residency, joined the pediatric hematology and oncology fellowship program at Memorial Sloan Kettering/New York Presbyterian-Weill Cornell. During her fellowship and early faculty years, Dr. Burke conducted research in the laboratory of Dr. Filemon Dela Cruz and Dr. Andrew Kung, where she leveraged patient-driven models to identify drivers and therapeutic vulnerabilities in pediatric cancers. Her preclinical work with selinexor, a selective inhibitor of the nuclear export protein exportin-1, contributed critical data that supported the current phase II investigator-initiated trial of selinexor in pediatric renal tumors. As a young investigator, she is passionate about applying novel computational approaches and tumor genomics to further elucidate the evolutionary dynamics of osteosarcoma. Dr. Burke seeks to leverage cutting-edge technologies in genomics to not only deepen our understanding of pediatric cancers but also to translate these insights into clinical practice.

KEY PRESENTERS



COREY WEISTUCH, PhD

Memorial Sloan Kettering Cancer Center

**Moderator: CURE-OS Working Group:
A blueprint for translating single
cell discoveries into better
osteosarcoma treatments**

I am an Assistant Attending Physicist in the Service for Predictive Informatics within the Department of Medical Physics at Memorial Sloan Kettering Cancer Center. My work is focused on developing mathematical models to understand cancer development, progression, and metastasis by integrating multimodal data. Central to this approach is the recognition that tumors occupy a finite spectrum of functional states, each characterized by distinct treatment sensitivities and metastatic tendencies that evolve over time and in response to therapy. My research centers on two primary objectives: 1) developing innovative mathematical tools to identify cancer phenotype drivers, and 2) precision modeling of cancer evolution and site-specific metastatic dissemination. By leveraging my interdisciplinary training in mathematics and biology, I collaborate closely with experimental biologists and clinicians to ensure that my computational predictions are effectively translated into tangible clinical applications and trials.



DAMON REED, MD

Memorial Sloan Kettering Cancer Center

**Osteosarcoma maintenance therapy
with OST31-164 (OST-164-01) -
Primary Results**



DAN REGAN DVM, PhD

Colorado State University

**Moderator: CURE-OS Working Group:
A blueprint for translating single
cell discoveries into better
osteosarcoma treatments**

Dr. Regan is a veterinary pathologist and Associate Professor in the Flint Animal Cancer Center and Department of Microbiology, Immunology, and Pathology at Colorado State University. The focus of Dr. Regan's laboratory is to increase our understanding of the interplay between the immune system and non-immune tumor stroma, and how these compartments of the tumor microenvironment (TME) promote metastasis as well as mediate extrinsic mechanisms of resistance to anti-cancer therapy, with a specific focus on macrophage-fibroblast cross-talk in osteosarcoma lung metastasis.



DAVID SHULMAN, MD

Dana-Farber Cancer Institute

Prospective evaluation ctDNA among patients with localized osteosarcoma identifies patients at high-risk of disease relapse: A report from the LEOPARD study

I am a Pediatric Oncologist and clinical/translational researcher at Dana-Farber Cancer Institute and an Assistant Professor of Pediatrics at Harvard Medical School. I am the Director of the DFCI AYA Sarcoma Program. My research is dedicated to improving outcomes for adolescents and young adults (AYAs) with sarcomas through investigation of novel approaches to therapy and circulating tumor DNA (ctDNA) as a clinical biomarker. My clinical focus is on the care of AYAs with sarcomas.



DAVID JENKINSON, PhD

LifeArc

Pediatric Bespoke Therapeutic Discovery Workshop on Osteosarcoma - Community Priorities

With 30 years' experience in oncology research, David joined LifeArc in 2023 to lead their efforts in childhood cancer. Following roles in academia and biotech, David joined Cancer Research Technology, introducing several innovative approaches, ensuring the progression of discoveries towards patients, including securing orphan designations, industry co-funding, and industry-academia drug discovery alliances. David then moved to The Brain Tumour Charity as CSO, where he transformed the scientific funding for the charity and grew the charity's international networks, establishing the organisation as the pre-eminent funder of research into brain tumours. Since joining LifeArc, he has established their strategy for the delivery of sustainable change in childhood cancers, established C-Further, the children's cancer therapeutic consortium, and worked with the community to explore the unmet needs in various cancers through a series of workshops.



EMANUELA PALMERINI, MD, PhD

Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami

Collaborative Data Ecosystems | FOSTER (Fight OsteoSarcoma Through European Research) Consortium

Precision Medicine | Prognostic and mifamurtide-related signatures for localized osteosarcoma: an ISG/OSZ trial correlative study of tumor immune microenvironment (TME)

Emanuela Palmerini is a medical oncologist interested in the care and research of bone and soft tissue sarcoma. She is currently appointed as Full Professor of Sarcoma Research at the Miller School of Medicine, University of Miami, Miami, FL, USA, joining the team of the Medical Oncology at the Sarcoma Sylvester Comprehensive Cancer Center. She coordinated the Clinical Trials Research at the IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy for almost 20 years and has acted as PI or co-I in more than 30 clinical trials in the treatment of sarcoma. She collaborated with the IRCCS Istituto Ortopedico Rizzoli Research Laboratories, with the European Institute of Oncology and with the Cell Therapy Unit and the Hemolymphopathology at the Institute of Hematology Seragnoli in Bologna, pioneering new treatments for these rare tumors. In 2016 she obtained PhD in Oncology, Pathology, Hematology at Bologna University. In May 2021, she was appointed the National Academic Qualification as Full Professor – Hematology, Oncology and Rheumatology (06/D3). She is member of several scientific societies including ASCO, ESMO, CTOS, EORTC, SELNET. In 2019, she was elected to the board of Director at European Musculoskeletal Oncology Society (EMSO) and to the European Organization of Cancer Research (EORTC) Bone Sarcoma Clinical Trial Working Group. From 2021 she has been on the Steering Committee of 2 groups within the Euro-Ewing Consortium. Since 2021 Dr Palmerini is co-Chair of the European Consortium for osteosarcoma FOSTER – Fight OsteoSarcoma Through European Research.

KEY PRESENTERS



EUGENIE KLEINERMAN, MD

UT MD Anderson Cancer Center

**Moderator: Integrative
Approaches to Advancing
Osteosarcoma Immunotherapies**

Eugenie S. Kleinerman, MD, a tenured Professor in Pediatrics and Cancer Biology at MD Anderson Cancer Center, holds the Mary V. and John A. Reilly Distinguished Chair. She earned an A.B. from Washington University in St. Louis, an M.D. from Duke University, completed her pediatric residency at Children's National in D.C., and a fellowship at the NCI. She was a Senior Investigator at NCI-Frederick before joining MD Anderson, where she led Pediatrics and the Children's Cancer Hospital (2001–2015). Internationally recognized for her osteosarcoma (OS) expertise, she pioneered MTP-PE immunotherapy for relapsed OS lung metastases, resulting in the first survival improvement in over 25 years, leading to EMA approval in 2009. Her research explores the mechanism of OS metastasis to the lung, the development of dendritic cell vaccines for relapsed OS, and the use of exercise to reduce Doxorubicin cardiotoxicity. Honors include awards from Duke, Wash U, MD Anderson, SIOP, and the Sarcoma Foundation.



GEOFFREY SMITH, MD, PhD

Boston Children's Hospital / Dana-Farber Cancer Institute and Massachusetts Institute of Technology

Evasion of endogenous CD8 T-cell responses in murine osteosarcoma



GREG SAWYER, PhD

Moffitt Cancer Center

3D patient avatars, cell therapy, and microscopic mayhem

Geoffrey Smith is a fellow in pediatric oncology at Boston Children's Hospital and Dana-Farber Cancer Institute. He did his MD and PhD at the University of California, where he identified a novel kinase inhibitor and used it to dissect T cell cytokine signaling in autoimmunity and cancer. He completed residency at Boston Children's Hospital and Boston Medical Center before joining the fellowship program at Boston Children's and Dana-Farber, where he witnessed firsthand the limitations of our current osteosarcoma therapies. After completing his clinical year, he joined the lab of Tyler Jacks at the Massachusetts Institute of Technology and initiated a new project studying immune response to murine osteosarcoma. He is a 2025 Damon Runyon-St. Jude Pediatric Cancer Research Fellowship Awardee and a 2025 St. Baldrick's Fellow. He will be an attending physician at Boston Children's / Dana-Farber beginning in July.

Greg Sawyer is a professor, engineer, scientist, cancer researcher, and cancer survivor who has turned his attention from space systems to exploring new frontiers in the battle against cancer. Greg was a member of the original Mars Rover design team at NASA's Jet Propulsion Laboratory, and his approach to cancer research follows a multidisciplinary team approach. A major goal of his research is to allow scientists to visualize and interact with cancer using bio-printing techniques and other tools pioneered in Soft Matter Engineering. Greg is a member of the National Academy of Inventors, Tribology Gold Medal winner, holds over 20 patents, has authored over 200 scientific publications, has been cited over 20,000 times, and has mentored dozens of PhD students – many of whom are now faculty members and researchers working at the interfaces between engineering, science, and biomedicine.



For every care in the community.



Cleveland Clinic proudly supports **MIB Agent's FACTOR 25** and its mission of advancing treatments and improving outcomes for osteosarcoma patients.

ClevelandClinic.org/Osteosarcoma



We Are Proud To Work Together To Conquer Kids' Cancer

The **St. Baldrick's Foundation** is a volunteer and donor powered charity committed to supporting the most promising research to find cures for childhood cancers and give survivors long and healthy lives.

stbaldricks.org



FACTOR 2024





KEY PRESENTERS



JAMES MORROW MD, PhD

Dana-Farber Cancer Institute

Dissecting the developmental origins of osteosarcoma

James is a pediatric oncologist and physician-scientist at Dana-Farber/Boston Children's Hospital. He completed his MD/PhD at Case Western Reserve University, his Pediatrics Residency at Boston Children's Hospital, and his Pediatric Hematology/Oncology Fellowship at Dana-Farber Cancer Institute. His graduate work identified enhancer dysregulation as a driver of osteosarcoma metastasis. His current research applies single-cell technologies to study the developmental origins and evolution of osteosarcoma. James is supported by a Damon Runyon-St. Jude Pediatric Cancer Fellowship, an Alex's Lemonade Stand Young Investigator Award, and a Rally Foundation Outside the Box Award.



JOHN A. LICON, MD

University of Florida

RNA prime - harnessing tumor RNA for immunotherapy against osteosarcoma

I earned my medical degree from the Baylor College of Medicine in Houston, completed my residency in pediatrics at the University of Texas Southwestern Medical Center in Dallas, and pursued a fellowship in pediatric hematology and oncology at Johns Hopkins University and the National Cancer Institute. In the following years, I completed a senior fellowship in pediatric immunotherapy at the National Cancer Institute and another in pediatric sarcoma at Johns Hopkins University. I am the Associate Director of the Pediatric Cancer Immunotherapy Initiative (PCI2) at the University of Florida, where I work to advance new treatments that harness the power of the immune system into early-phase pediatric clinical trials.



JOHN OKELLO, PhD, MBA

BTC: Break Through Cancer

BTC Osteosarcoma TeamLab

John B. A. Okello, PhD, MBA, serves as a Scientific Portfolio Manager at Break Through Cancer, bringing extensive expertise in scientific research, strategic management, and healthcare leadership. Rooted in molecular biology, genetics, and rare inherited diseases research, John earned his Ph.D. in Molecular Genetics from Makerere University. He furthered his expertise with a postdoc at McMaster University and, more recently, earned an MBA through the MIT Sloan Fellows Program at the Sloan School of Management, with an MIT Healthcare Certificate. Before joining Break Through Cancer, John played pivotal roles in leading academic medical research institutions, including SickKids Hospital and Queen's University Cancer Research Institute in Canada. His background involved benchwork, bioinformatics, and research management, including fostering complex biomedical research collaborations and translation. Committed to scientific program management, strategic vision, and transformative healthcare initiatives, John is passionate about contributing to Break Through Cancer's mission and its dedication to facilitating impactful advancements in the fight against cancer through radical research collaboration.



JOSHUA SCHIFFMAN, MD

University of Utah and Peel Therapeutics, Inc.

Moderator: Biological Drivers of Osteosarcoma

Dr. Schiffman is the CEO and Co-Founder of Peel Therapeutics, a biotech company that delivers evolution-inspired medicine to patients. Dr. Schiffman is also a Professor of Pediatrics and Investigator at Huntsman Cancer Institute at the University of Utah. He works as a Pediatric Hematologist-Oncologist at Intermountain Primary Children's Hospital in Salt Lake City, Utah. Dr. Schiffman graduated from the Brown University School of Medicine in 2000, followed by clinical training in Pediatrics and Pediatric Hematology-Oncology at Stanford University from 2000-2008. His academic research and now biotech efforts focus on engineering evolution for patients with cancer, and studying animals that are naturally protected from disease, like elephants. Dr. Schiffman focuses on osteosarcoma and other pediatric diseases with a commitment to impact diagnosis, treatment, and prevention.



JOVANA PAVISIC, MD

Memorial Sloan Kettering Cancer Center

Moderator: CURE-OS Working Group: A blueprint for translating single cell discoveries into better osteosarcoma treatments

Dr. Pavisic is a pediatric oncologist on the Sarcoma Service in the Department of Pediatrics at Memorial Sloan Kettering. She earned her MD from Yale University, completed pediatrics residency at Stanford Children's Hospital, and fellowship in pediatric hematology/oncology at Columbia, where she also completed a postdoctoral fellowship and masters program in Biomedical Informatics. Her research applies computational approaches to study tumor gene expression data, including at the single-cell level. In osteosarcoma, she is using systems biology algorithms to develop prognostic and therapeutic biomarkers. This includes studying single-cell RNA sequencing to predict drugs targeting unique tumor cell states for clinical translation of novel combination therapy approaches targeting tumor heterogeneity. She co-leads the MIB Agents CURE-OS single-cell working group, advancing single-cell technologies to find better treatments for osteosarcoma.



KATIA SCOTLANDI, PhD

IRCCS Istituto Ortopedico Rizzoli

Molecularly-driven information on patient-derived xenografts (PDX) and cell lines leads to ixabepilone repurposing for resistant osteosarcoma

My research work has been focused on pediatric solid tumors, particularly bone sarcomas. The goal of my research activity is to contribute to the definition of biomarkers of risk and response that allow more personalized therapeutic approaches against Ewing sarcoma and osteosarcoma and to pave the way for accelerating the discovery of the most promising biologically and epigenetically-targeted drug. My main achievement is, however, the creation of a research lab specifically devoted to studying bone tumors that has obtained worldwide recognition. From 2016 to 2019, I served as Secretary of the WG Sarcoma inside the Italian Alliance against Cancer, the oncologic network of the Italian Ministry of Health, to coordinate preclinical research activities. No less important, it is my mentoring activity inside academia. Over the years, I have followed over seventy post-doctoral fellows and junior faculty members, contributing to diffusing knowledge on paediatric oncology.

KEY PRESENTERS



KATIE ALBERT, MD

Seattle Children's Hospital, University of Washington

Moderator: Clinical Trials

Dr. Katie Albert is an Associate Professor at the University of Washington School of Medicine and an attending physician at Seattle Children's Hospital, where she serves as the medical director of the solid tumor team and co-leads the multidisciplinary sarcoma program. She received her undergraduate degree from Brandeis University and her medical degree from the George Washington University School of Medicine. She completed her residency training at Johns Hopkins University and her fellowship in pediatric hematology/oncology through the Johns Hopkins University/National Cancer Institute combined program. While a fellow and junior faculty at JHU, she worked in the lab of David Loeb, studying molecular targets of pediatric sarcoma with a focus on rhabdomyosarcoma. Since joining the faculty at Seattle Children's/UW, her research focus has been on the development and conduct of immunotherapy clinical trials for high-risk pediatric and young adult solid tumors.



KATIE JANEWAY, MD, MMSc

Dana-Farber Cancer Institute

Directly engaging participants in rare cancer research is feasible: The Osteosarcoma Project

Dr. Janeway received her MD and MMSc from Harvard Medical School. She completed her pediatrics residency and her Pediatric Hematology-Oncology fellowship at Boston Children's Hospital and Dana-Farber Cancer Institute. She is an Associate Professor of Pediatrics, a Senior Physician who cares for young people with sarcoma, and Director of Clinical Genomics. Dr. Janeway's research is focused on precision oncology and bone sarcomas. She leads clinical trials both as an independent investigator and as the Chair of the Children's Oncology Group (COG) Bone Tumor Committee. The Janeway Laboratory leads several studies, which have enrolled and sequenced more than 2,500 patients with childhood cancers. They are using this data to deepen the understanding of clinical and genomic factors explaining prognosis and treatment response, and resistance with a focus on sarcomas. In collaboration with Count Me In, the group is innovating patient partnerships in sarcoma research.



KELLY GUTPELL, MBCh, PhD

Nationwide Children's Hospital

Characterization of the anchor cell in preclinical models of metastatic osteosarcoma

Kelly Gutpell is a Pediatric Hematology and Oncology Fellow at Nationwide Children's Hospital. She joined Dr. Ryan Roberts' lab earlier this academic year and is currently conducting her research project, which is focused on using single-cell technology to characterize the anchor cell in metastatic osteosarcoma. Upon completion of her Hem/Onc Fellowship, Kelly's goal is to pursue a career as a physician-scientist and conduct translational research that can one day significantly impact the lives of our young sarcoma patients.



KEVIN JONES, MD

University of Utah, Huntsman
Cancer Institute

**Epigenetics and osteosarcoma
oncogenesis**

**Moderator: SARC and Other Sarcoma
mentorship and coaching for young
investigators in sarcoma research**

Kevin studied English literature at Harvard and medicine at Johns Hopkins. After training in orthopaedic surgery at the University of Iowa and in surgical musculoskeletal oncology at the University of Toronto, he came to the University of Utah Department of Orthopaedics as a faculty surgeon. In parallel to his surgical practice providing care for pediatric and adult bone and soft-tissue sarcomas, five years of mentored scientific training with Mario Capecchi led to the establishment of Dr. Jones' independent laboratory at Huntsman Cancer Institute. His National Cancer Institute-funded laboratory studies the epigenetics of transcriptional regulation in sarcoma, using mouse genetic models of sarcomagenesis. He holds the L. B. and Olive S. Young Presidential Endowed Chair for Cancer Research and is a Professor with tenure in the Department of Orthopaedics, as well as an Adjunct Professor in the Department of Oncological Sciences.



KRISTEN VANHEYST, DO

University Hospitals/Rainbow Babies and
Children's Hospital

**Targeting TGF-beta signaling in the
tumor microenvironment as an effective
therapy in osteosarcoma**

Dr. Kristen VanHeyst is a Pediatric Oncologist at University Hospitals/ Rainbow Babies & Children's Hospital. She is also a member of the Immune Oncology program at Case Comprehensive Cancer Center. She joined the faculty at Rainbow Babies & Children's Hospital after completing her clinical fellowship there in 2019. As a member of Dr. Alex Huang's laboratory, she focuses on preclinical experiments in metastatic osteosarcoma. She continues to develop clinical trials both locally and in collaboration with pharmaceutical companies and national consortia in an attempt to improve treatment options for pediatric, adolescent, and young adult patients with sarcomas. She has had the honor of being an MIB Agents Outsmarting Osteosarcoma Young Investigator award recipient, among other foundation awards. She is excited to once again be speaking at FACTOR this year.



KURT R. WEISS, MD

University of Pittsburgh and UPMC
Hillman Cancer Center

Moderator: Patient Panel

Dr. Kurt R. Weiss is an Associate Professor in the University of Pittsburgh Department of Orthopaedic Surgery, Division of Musculoskeletal Oncology, with joint appointments in Surgical Oncology and Pathology. He is an Advisory Dean at Pitt's School of Medicine and Vice Chair of Translational Research. His Musculoskeletal Oncology Lab (MOL) focuses on sarcoma metastasis, using samples from the Musculoskeletal Oncology Tumor Registry and Tissue Bank (MOTOR), founded in 2012, now holding 18,000+ samples from 600+ sarcoma patients. Dr. Weiss has authored 80+ peer-reviewed papers and serves on SARC's Scientific Steering Committee, CTOS's Mentorship Committee (former Board member), and chaired the MSTS Research Committee. He served on the inaugural DoD Rare Cancers Research Program Panel. He co-founded Pittsburgh Cure Sarcoma and the Pittsburgh Sarcoma Research Collaborative. A metastatic osteosarcoma survivor, he credits his survival to MTP-PE treatment under Dr. Eugenie Kleinerman.

SCIENCE > SARCOMA



Nationwide Children's Hospital is a proud sponsor of the MIB Agents FACTOR conference and dedicated partner in our pursuit to improve outcomes for patients everywhere.


To learn more about our program, visit
NationwideChildrens.org/Sarcoma



214-286-6888

www.QuadW.org

In 2006, the Tichenor family created the QuadW Foundation in loving memory of Willie Tichenor, who bravely faced three years of treatment for osteosarcoma. He left an indelible mark on his community and inspired his friends to serve on the QuadW Foundation board alongside his parents and brother. They have worked together to pave the way for better sarcoma treatment options and support causes that reflect and honor Willie's light-hearted but whole-hearted spirit.



HIGHER EDUCATION

QuadW has provided over 60 students with scholarships to pursue higher education, music, and study abroad opportunities.

TRANSFORMATIVE MISSION

QuadW funds mission opportunities where young adults perform a variety of service work around the world.

GENERAL PHILANTHROPY

QuadW is a supporter of projects meeting the needs of underserved communities in Willie's hometown of Dallas.

SARCOMA RESEARCH

QuadW has an extensive sarcoma grant research portfolio resulting in over 135 publications and the founding of the Osteosarcoma Institute (OSI).

WE ARE GRATEFUL FOR EDWARD CHEUNG AND LAIMAN WONG'S GENEROUS SUPPORT

of our video recordings at FACTOR 2025. Their contribution ensures that the valuable insights and presentations from all sessions will be captured and available post-conference on our YouTube channel for broader access and continued learning. Thank you to Isaac Cheung's family for helping us share this vital information with the global osteosarcoma community.

#BecauseOfIsaac

KEY PRESENTERS



LARA DAVIS, MD

Knight Cancer Institute, Oregon Health & Science University

Moderator: SARC and Other Sarcoma mentorship and coaching for young investigators in sarcoma research



LU XIE, MD

Peking University People's Hospital

Collaborative data ecosystems in mainland China



MASANORI HAYASHI, MD

University of Colorado

Correlative studies from NPCF Phase II trial of gemcitabine and nab-paclitaxel for recurrent osteosarcoma.

Lara Davis, MD, is an Associate Professor at Oregon Health & Science University (OHSU), where she is the Sarcoma Program Director and co-leads the Translational Oncology Program of the Knight Cancer Institute. She completed combined fellowship training in Medical Oncology and Pediatric Hematology/Oncology in order to pursue a career in adolescent and young adult sarcoma care. Dr. Davis runs a number of sarcoma clinical trials and conducts translational osteosarcoma research. She is a member of SARC's Scientific Steering Committee, chairs the Osteosarcoma Institute's Brokers of Progress Committee, and is chair of SWOG's Sarcoma Working Group.

Lu Xie, Pediatric Oncologist for Sarcoma, Deputy Medical Director, Musculoskeletal Tumor Center, Clinical Associate Professor, Master Supervisor, Peking University. Major in targeted therapy for osteosarcoma as well as immunotherapy. For translational study, she is interested in biomarker investigation and tumor microenvironment for osteosarcoma.

Dr. Masanori Hayashi is a pediatric oncologist, physician scientist at the University of Colorado/Children's Hospital Colorado, leading a translationally focused laboratory research program in childhood sarcomas. His laboratory has been focused on developing liquid biopsy tests in sarcomas, as well as developing novel anti-metastasis strategies for sarcomas. Combined with his expertise in developing novel blood tests of minimal residual disease through the detection of circulating tumor DNA and circulating tumor cells, his laboratory aims to change the current treatment paradigm by detecting metastasis early and treating metastasis differently to improve the cure rates of sarcomas. Dr. Hayashi is a graduate of Keio University School of Medicine in Tokyo and completed his pediatric residency training at Duke University, followed by his pediatric hematology/oncology fellowship training at the joint program of Johns Hopkins University and the National Cancer Institute.

KEY PRESENTERS



MATHIEU EPINETTE

Koch Institute for Integrative Cancer Research at MIT

Heterogeneous and ongoing genomic rearrangements in a murine osteosarcoma model parallel human disease.

Mathieu Epinette is a research technician in the Jacks Lab at the Massachusetts Institute of Technology. He earned his Bachelor of Science degree from Northeastern University, where he gained research experience as an undergraduate researcher at Mink Therapeutics and Dragonfly Therapeutics. He now works alongside a pediatric oncology fellow to investigate the genetic underpinnings and immune response in murine osteosarcoma. He will be pursuing his PhD in the Biological and Biomedical Sciences program at Harvard University this fall.



MATTEO TRUCCO, MD

Cleveland Clinic, Case Western Reserve University

FACTOR 2025 Co-Chair

Matteo Trucco is a Pediatric Oncologist caring for children, teens, and young adults with sarcomas at Cleveland Clinic Children's. He also serves as Clinical Director, directs the Children's Cancer Innovative Therapy Program, and co-chairs the National Pediatric Cancer Foundation's Sunshine Project consortium where he and colleagues develop and conduct clinical trials seeking more effective and less toxic treatments for childhood cancers. He got his undergraduate degree from the University of Pennsylvania, Medical Degree from Temple University School of Medicine, completed Pediatrics Residency at Rainbow Babies and Children's Hospital, and Pediatric Hematology/Oncology Fellowship at Johns Hopkins and the National Cancer Institute. He is honored to be on the MIB Agents Board, chairs its Scientific Advisory Committee, and co-chairs the organizing committee for the FACTOR Conference. He also has the privilege of moderating the MIB Agents Tumor Review Board for Osteosarcoma (TURBO).



MATTHEW DIETZ, DO, MSED

University of Utah/Primary Children's Hospital

Prognostic significance and microenvironment influence of cMYC in osteosarcoma

Dr. Dietz is an Assistant Professor of Pediatrics in the Division of Pediatric Hematology and Oncology at the University of Utah. Clinically, Dr. Dietz focuses on the care of pediatric and young adult patients with bone and soft tissue sarcoma, as well as children with retinoblastoma. He leads Primary Children's Hospital's Solid Tumor Clinical Trial Enterprise and directs the Comprehensive Retinoblastoma Program. Dr. Dietz is committed to delivering cutting-edge clinical care, as well as providing patients with access to experimental therapeutics and discovery programs. Dr. Dietz's research efforts include team science approaches to better understand the biology driving cancer and treatment resistance, with a focus on translating this work into new therapies. He is a member of the Huntsman Cancer Institute's Experimental Therapeutics Program and is actively involved in the development of early-phase clinical trials through multiple cooperative consortia.



MICHAEL LIZARDO, PhD

BC Cancer

Inhibition of the mitochondrial oxidative stress response in metastatic osteosarcoma cells prevents growth in murine lung tissue

Dr. Michael Lizardo is currently a staff scientist in the laboratory of Dr. Poul Sorensen, in the Department of Molecular Oncology of BC Cancer, in Vancouver, BC, Canada. Michael completed his Ph.D. in Medical Biophysics under the supervision of Drs. Ann F. Chambers and Ian C. MacDonald at Western University, where he developed imaging models of lymph node metastases. After his graduate studies, Michael pursued post-doctoral research in the laboratory of Dr. Chand Khanna in the Pediatric Oncology Branch of the National Cancer Institute, National Institutes of Health, in Bethesda, Maryland. His post-doctoral research focused on osteosarcoma (OS) lung metastasis and studying the OS ER-stress response as a metastatic vulnerability. After his post-doctoral work, Michael joined Dr. Poul Sorensen's research group, where he continues to study stress adaptation pathways in metastatic OS and find druggable targets for the development of novel anti-metastatic therapies.



REBECCA MAKII, MS, DVM, DACVP

Colorado State University

A comparative understanding of oncogenic MYC signaling in the metastatic osteosarcoma tumor immune microenvironment

Dr. Rebecca Makii is a board-certified veterinary pathologist, postdoctoral fellow, and PhD student in Dr. Dan Regan's Investigational pathology laboratory at Colorado State University's Flint Animal Cancer Center. She earned her Master's in Comparative Medicine and DVM at The Ohio State University before completing a residency in anatomic pathology at Colorado State University. Her research focuses on the spatial organization of metastatic osteosarcoma and how tumor cells, the immune system, and surrounding stroma interact to promote therapeutic resistance.



RICHA KAPOOR, PhD

Children's Hospital of Philadelphia

Defining the immunopeptidome of osteosarcoma nominates candidate therapeutic targets

Dr. Richa Kapoor is a Staff Scientist II working with Dr. John M. Maris at the Children's Hospital of Philadelphia, Philadelphia, PA. Richa is an immune oncologist and pursued her post-doctoral training in immunology and oncology at the Perelman School of Medicine at the University of Pennsylvania, Philadelphia. She is a passionate researcher engaged in the identification of novel targets and developing immunotherapies to treat solid tumors.

KEY PRESENTERS



ROBERT GATENBY, MD

H. Lee Moffitt Cancer Center



ROSANDRA N. KAPLAN, MD

National Cancer Institute/
National Institutes of Health



SAM VOLCHENBOUM, MD, PhD

University of Chicago

Moderator: Mechanisms of Resistance and Evolution

Bob received a B.S.E. in Bioengineering and Mechanical Sciences from Princeton and an M.D. from the University of Pennsylvania, where he also completed a radiology residency and served as chief resident. He remains an active body imaging radiologist. At Fox Chase Cancer Center, Bob saw oncology flooded with data but lacking unifying frameworks. Drawing on his engineering background, he viewed cancer as a complex dynamic system and began using mathematical models and computer simulations to uncover governing principles in cancer biology and treatment. In 2008, he joined Moffitt as chair of radiology and led the creation of the Integrated Mathematical Oncology (IMO) department. Now with 8 faculty mathematicians and over 20 postdocs and grad students, IMO has formed multidisciplinary teams across oncology, surgery, pathology, imaging, biology, and evolution. IMO researchers co-lead two clinical trials using evolutionary dynamics and modeling to guide therapy, making Moffitt unique in fully integrating modeling into cancer science and care.

Moderator: Tumor Heterogeneity and Microenvironment Interactions

Rosandra Kaplan, MD is a senior investigator and Head of the Tumor Microenvironment and Metastasis Section and leads the Solid Tumor Immunotherapy Program in the Pediatric Oncology Branch, in the Center for Cancer Research in the National Cancer Institute in the National Institutes of Health. She is a physician scientist, and her areas of interest include the tumor microenvironment and its role in dictating metastatic progression, myeloid and stromal cell biology and immunotherapy. She leads the CTEP sponsored multi-site GD2 Chimeric Antigen Receptor (CAR)-T cell therapy trial for pediatric and young adult patients with Osteosarcoma and Neuroblastoma. Her clinical focus is on solid tumor immunotherapy and microenvironmental targeting. She is initiating a first in human myeloid cell therapy trial for relapsed, refractory solid tumors that is directly translated from her laboratory efforts. Dr. Kaplan loves to mentor the next generation of clinical and translational scientists.

Moderator: Collaborative Data Ecosystems

Dr. Volchenboum is a professor of pediatrics and the associate chief research informatics officer for the Division of Biological Sciences at the University of Chicago. He is the Associate Dean of Masters Programs, and he designed and launched the UChicago Master's in Biomedical Informatics. His clinical specialty is pediatric hematology/oncology, caring for kids with cancer and blood diseases. His research group includes the University of Chicago's Data for the Common Good (D4CG), dedicated to building communities, platforms, and ecosystems that maximize the potential of data to drive discovery and improve human health. D4CG's flagship project, the Pediatric Cancer Data Commons, is dedicated to liberating and democratizing international data for pediatric malignancies. He is the director of the Informatics Core for the Clinical and Translational Science Award (CTSA), and he is the Director of the UChicago Clinical Informatics fellowship program.



SANDRA STRAUSS, MD, PhD
UCL Cancer Institute

ICONIC: Improving outcomes through collaboration in osteosarcoma

Sandra Strauss is Professor of Medical and TYA Oncology and a consultant Medical Oncologist at University College London Hospital, part of the London Sarcoma Service, one of the largest sarcoma services in Europe. She leads the clinical service and specialises in the systemic treatment of sarcomas in both adults and teenagers. She has over 15 years' experience as a chief and principal investigator for international and national clinical trials and is leading a UK national cohort study in osteosarcoma, ICONIC. She is an executive Committee member of FOSTER (Fight Osteosarcoma through European Research) and chairs the executive committee of the EuroEwing consortium (EEC), both pan-European collaborations that have brought together clinicians, scientists, and patient advocates to improve outcomes for patients with osteosarcoma and Ewing sarcoma, respectively. She is also the National Clinical Lead for Sarcoma for the National Disease Registration Service (NDRS) and is the current track chair of the European Society of Medical Oncology (ESMO) sarcoma track.



SASHA BLAY, PhD CANDIDATE
The Hospital for Sick Children

Harnessing mutational signatures to pinpoint the development of chemoresistance in metastatic and relapsed osteosarcoma

Sasha is a graduate student researcher in the Shlien lab at the Hospital for Sick Children and at the University of Toronto, Canada. She harnesses cutting-edge bioinformatic techniques to investigate 'omics data of rare and aggressive pediatric cancers to better understand chemoresistance. Sasha has combined clonal evolution reconstruction with mutational signature analysis to pinpoint signals of therapeutic resistance in tumours and patient plasma. Passionate about advancing diagnostic techniques and personalised medicine, Sasha is proud to be exploring and adapting machine learning tools for Canadian clinical practice.



SCOTT OKUNO, MD
Mayo Clinic

Moderator: SARC and Other Sarcoma mentorship and coaching for young investigators in sarcoma research

Scott H. Okuno, M.D., is a medical oncologist with a specialty interest is in bone and soft tissue sarcoma. His clinic focus includes: Managing sarcoma patients in a multi-disciplinary approach; Providing access to clinical trials for patients; Advocate for sarcoma support groups; Managing and overseeing the development and conduct of clinical trials; Assisting oncologists in managing the care of patients locally when appropriate. In addition to his clinical activities, Dr. Okuno is active in research, education, and mentorship to residents, fellows, and junior staff. He published articles in high-impact scientific journals. Dr. Okuno is Chair of the Division of Community Oncology for the Department of Oncology and is Chair of the Mayo Clinic Health System Cancer Committee. He actively practices at Mayo Clinic Rochester and the Mayo Clinic Health System. He is the Chief Medical Officer for SARC.

WE PERSEVERE

KEY PRESENTERS



SHAHANA MAHAJAN, PhD

Hunter College, City University of New York



SOWMYA RAMESH, PhD

Johns Hopkins University



YOGESH BUDHATHOKI, MS

Nationwide Children's Hospital

Repurposing drugs for osteosarcoma

I earned a Ph.D. from the Indian Institute of Science, a premier Institute in India in the field of Molecular Biology. I studied the transcription regulation of two genes induced by phenobarbitone in rat liver. I did postdoctoral studies at Weill Cornell Medical College in the department of Pharmacology and at NYU Langone Medical Center in the department of Biochemistry. My postdoctoral research focused on the control of cell proliferation by Host cell factor (HCF-1) initially, and subsequently moved to neuroscience to investigate glutamate-induced excitotoxicity in rat hippocampal neurons. I joined Hunter College as an Assistant Professor in 2007 in the Department of Medical Laboratory Sciences. At Hunter, I continued my research in neuroscience until 2012, when my lab was destroyed by Hurricane Sandy. I was promoted to Associate Professor in 2014. In 2015, my lab moved to the Belfer Research Building of Weill Cornell Medical College, where I initiated the work on osteosarcoma. In 2023, I was promoted to a full Professor and in 2024 was elected as the Department Chair.

Sensory neurons regulate osteosarcoma disease progression

Dr. Ramesh is a postdoctoral researcher from the James lab at Johns Hopkins. The lab's research focus lies at the intersection of skeletal pathophysiology and stem cell biology. They look at the interaction of nerves in various musculoskeletal repairs, including bone repair and regeneration, osteoprogenitor cell characterization, and neoplastic bone. Dr. Ramesh specifically works on understanding how peripheral nerves regulate osteosarcoma disease progression.

Project OsteoCAR: Building a comprehensive resource for cell type annotation and transcriptomic exploration of osteosarcoma

Yogesh is a doctoral student enrolled in the Molecular, Cellular, and Developmental Biology (MCDB) Program at The Ohio State University. He obtained his undergraduate degree with a double major in Biology and Chemistry from Berea College in May 2022. He is a part of the Roberts' lab, which studies pediatric sarcomas at Nationwide Children's Hospital. His research interests include exploring the intricacies of genetic and epigenetic alterations contributing to osteosarcoma tumor heterogeneity, metastasis, and therapy resistance by leveraging a blend of wet-bench and computational approaches.

THEIR FIGHT. OUR MISSION.

Pioneering together
for a cancer-free
tomorrow.

gene.com



OUTSMARTING OSTEOSARCOMA 2025

\$100K HERO GRANT RECIPIENTS



ALEXANDER DAVIES, DVM, PhD

Oregon Health & Science University

Validation of MCL1 inhibition and combinatorial therapy for elimination of osteosarcoma lung metastasis

Funded in partnership with Fishin' for the Cure
#BecauseOfMatthew



AMY LEBLANC, DVM

National Cancer Institute

A comparative approach to exploring fluorescence *in situ* hybridisation (FISH) biomarkers for advancing the diagnosis, prognostication and treatment of osteosarcoma



COREY WEINSTUCH, PhD

Memorial Sloan Kettering Cancer Center

Implementing personalized, adaptive therapies in osteosarcoma



DAVID ULMERT, MD, PhD

University of California, Los Angeles

High-throughput characterization of pathobiological responses in osteosarcoma tumors treated with LRRC15-targeted radiotherapy to uncover curative co-treatment approaches

#BecauseOfSydney

\$50K HOPE YOUNG INVESTIGATOR GRANT RECIPIENTS



RAM RAO, MD, PhD

Seattle Children's Research Institute

**Extracellular matrix degradation to overcome
osteosarcoma chemoresistance**



JOSEPH SKEATE, PhD

University of Minnesota

**Next generation dual-CAR gamma delta T cells for
the treatment of pediatric osteosarcoma**

#BecauseOfAnnaleigh



ALI CIHAN, PhD

Memorial Sloan Kettering Cancer Center

**Targeting EPHA2 with dual-armored CAR T cells
for immunotherapy in pediatric osteosarcoma**

#BecauseOfIsaac



JANEALA MORSBY, PhD

St. Jude Children's Research Hospital

**Synergy of ATM and PARP inhibitors in
pediatric osteosarcoma**

#BecauseOfBuddy



ANDREW S. CLUGSTON, PhD

University of California, San Francisco

**Oncogenic structural variation in the
genome of pediatric osteosarcoma**



AAFRIN M. PETTIWALA, PhD

University of California, San Francisco

**Identifying mechanisms of
chemoresistance in metastatic osteosarcoma
using molecular barcoding**

Funded in partnership with the RISE Foundation

#BecauseOfReese

HONORING THE FAMILY FUNDS POWERING OUTSMARTING OSTEOSARCOMA

The OutSmarting Osteosarcoma grant program would not be possible without the extraordinary generosity and dedication of the MIB Agents Family Funds—families who have turned their love for an OsteoWarrior or OsteoAngel into hope for every child facing osteosarcoma. We are deeply grateful to each Family Fund that has contributed to advancing research toward better, kinder treatments.

Because Of Aiden, Alex, Allisen, Andrew, Annaleigh, Arnav, Ava, Avery, Brenton, Briana, Brooke, Brooklynn, Buddy, Cameron, Carson, Charlotte, Chris, Christien, Clayton, Daniel, Dylan, Edward, Eli, Ella, Gavin, Ian, Isaac, Jack, Jaden, Krysty Bujakowka, Kyle, Leah Chelsky, Marisa, Matthew, Megan, Mia, Michael, Mohan, Natalie, Nicholas, Reese, Ryan K., Ryan T., Seth, Sloane, Sydney, Tyler M., Tyler Y., Victor, Victoria, Zachary


This year, we are especially honored to recognize the Family Funds who have gone above and beyond to fully sponsor entire grants: Because of Annaleigh, Because of Buddy, Because of Isaac, Because of Sydney, and in partnership with the RISE Foundation, Because of Reese. Their commitment has directly enabled scientists to pursue bold ideas with the potential to change the trajectory of this disease.

THE POWER OF WILL

SUPPORT AND ENHANCE THE LIVES OF SARCOMA PATIENTS AND THEIR LOVED ONES

Established in honor of Will Hudson, The Power of Will is dedicated to changing the narrative for sarcoma patients. We focus on funding scientific research, providing educational resources, and offering financial assistance to adolescent and young adult sarcoma patients through our Quality of Life Grants.

JOIN US IN OUR MISSION TO FIND BETTER TREATMENTS AND IMPROVE OUTCOMES FOR SARCOMA PATIENTS. TOGETHER, WE CAN MAKE A DIFFERENCE.



Visit our website
thepowerofwill.org



BECAUSE OF ANNaleigh

After our 18-year-old daughter, Annaleigh, passed from osteosarcoma, we found a will she had written on her phone. She requested that the money she saved be donated to help other children battling osteosarcoma. We are grateful to fund a grant in Annaleigh's name, honor her wishes and allow her legacy to continue. We miss Annaleigh every day, but the opportunity to make it better for others fighting this disease helps us heal. Thank you MIB.



BECAUSE OF BUDDY

This journey has shown us both the brutality of osteosarcoma and the strength of community. Determined to help other families facing this diagnosis and to support the search for better treatments and a cure, we established a Family Fund with MIB Agents. Through this partnership, we're proud to support initiatives like the OutSmarting Osteosarcoma grant, which funds innovative research and offers hope where it's most needed.



BECAUSE OF ISAAC

Through the OutSmarting Osteosarcoma Hope YI Award, we stand alongside the brilliant minds working toward that goal, believing wholeheartedly that breakthroughs are within reach. This funding is more than just a grant—it is love, perseverance, and hope, embodied. It is Isaac's impact, still alive in every stride we take forward. Because of Isaac, this work continues. Because of Isaac, we move forward in pursuit of a cure.



BECAUSE OF SYDNEY

Sydney was always a thoughtful, loving, giving person and through generous friends and family she continues to give back by funding this Hero Award. We are excited to fund Dr Ulmert's research and believe his work has the potential to change the outcomes for unresectable tumors like Sydney's.



BECAUSE OF REESE

During Reese's battle, MIB provided support and resources in a kind and compassionate way. This year we are supporting the promising work of Dr. Andrew Clugston, whose goal is to develop tumor-specific therapeutic targets and design precision treatments for osteo. This research spoke to our hearts as our son desperately needed this approach for his chemo-resistant tumors. We are grateful to partner with Dr. Clugston, in honor of our courageous son, Reese Irnhoff.



BECAUSE OF MATTHEW

This grant is especially meaningful to us because it is given in honor and memory of Matt and all the osteo angels who have left this world far too soon. Their strength continues to inspire everything we do. Supporting your research is one way we keep their legacy alive — by fighting for a future where better treatments and brighter outcomes are possible.



SENIOR LEADERSHIP TEAM



**Executive Director
MIB Board of Director**

ANN GRAHAM

Ann is the founder and Executive Director of MIB Agents. At age 43 she was diagnosed with osteosarcoma. She was treated in the pediatric cancer center at Memorial Sloan Kettering in NYC where she was awed and inspired by the courage and cheerfulness of the kids she was treated with. Today as a survivor, and together with MIB Agents everywhere, the mission to Make It Better (MIB) for kids with osteosarcoma is wholeheartedly undertaken. Ann serves on the SARC Board of Directors, NCCN Bone Tumor Panel, ACCELERATE - FAIR Working Group and on the Advocate Alliance Leadership Council with the A2A Alliance and with The Mighty.



Director of Scientific Programs

CHRISTINA IP-TOMA

Christina's son Dylan passed away in 2021 when he was 14, after bravely battling osteosarcoma for five years. Christina joined the MIB Agents team in January 2022 as the Director of Scientific Programs, after a career in marketing and operations for internet start-ups. In addition to being a proud owner of a MIB Agents Family Fund honoring Dylan, she is also a founding member of the Battle Osteosarcoma team that has partnered with St. Baldrick's Foundation to fund over \$3 million in osteosarcoma research grants since 2019. She is honored to serve as a consumer reviewer for the CDMRP, a Count Me In Stakeholder Advisory Group member, and a Research Advocate on the NCI Human Tumor Atlas Network (HTAN). She is grateful to MIB Agents and these programs for giving her the opportunity to make it better for OsteoWarriors and pediatric cancer patients, which is helping her transform senseless loss into a sense of purpose - #BecauseOfDylan.



Director of Finance

CAROLYNE RICHTARSIC

Carolyne Richtarsic joined MIB in 2022 as the Director of Finance. In addition to owning her own Accounting Services firm, she has over a decade of non-profit fundraising and management experience. She has been confronted by the realities of a cancer diagnosis of those she loves and because of this is passionate about ensuring that MIB is maximizing every dollar toward the goal of beating osteosarcoma.



Director of Programs

ISABEL WOLF

Isabel Wolf joined MIB Agents in April of 2021 where she serves the osteosarcoma community as MIB's Director of Programs. She came to MIB via the Matthew Lehrman Osteosarcoma Fund. OsteoAngel Matthew called her "My second Mom." Isabel was an artist manager of opera singers and classical musicians for more than 30 years and has served on not-for-profit boards of directors in the US and Europe. She vowed to Matthew that she would help Make it Better for other children and their families, suffering with osteosarcoma.

**Fundraising & Events Manager****ANITA CALDERA**

Anita Caldera joined MIB Agents as Fundraising and Events Manager in May of 2022. She has worked in the non-profit space for over 15 years, leading with compassion and advocating for families navigating Early Intervention Program and executing small to mid-scale events with the National Hemophilia Foundation. She is passionate about wellness, building relationships and continues to Make It Better for families facing osteosarcoma alongside her teammates and MIB Agents everywhere.

**Social Media Manager & Junior Advisory Board Manager****KARA SKRUBIS**

Kara is the MIB Agents Social Media and Junior Advisory Board Manager. She was diagnosed with osteosarcoma in January of 2020, and underwent 9 months of chemotherapy, a left above-the-knee amputation, and 8 months of immunotherapy. She went on to serve on the MIB Agents JAB for three years, becoming the president in 2022, and then joining the staff. She takes pride in all that MIB Agents does for the community, and our work to Make It Better!

**Marketing & Development Assistant****HANNAH HESS**

Hannah Hess is proud to be serving as the Assistant of Marketing and Development at MIB Agents. Currently studying Hospitality Administration and Music at Boston University, Hannah is passionate about spreading hope alongside her colleagues and the amazing MIB community. Hannah is proud to produce MIB's monthly Family Fund newsletter, aid in grant applications, and work with the generous sponsors of FACTOR 2025.

**MIB Agents Brand Ambassador****JOEL MADDEN**

Good Charlotte
The Madden Brothers
Rock Star Ink Master Host
The Voice Australia Coach

BOARD OF DIRECTORS

ANN GRAHAM

OsteoWarrior

Executive Director, MIB Agents

ALEXIS JOHNSON, MD

OsteoWarrior

Pediatric Resident, UCSD, Rady Children's Hospital-San Diego

BETH ODEH-FRIKERT, PHARM.D

Corporate Business Development at Genentech

GIGI JEFFRIES, PH.D

GREG KAPLAN, CFA

Dad to Sydney who battled osteosarcoma for over 2 years

Global Head of Fixed Income Portfolio Management, Jefferies

JOHN H. HEALEY, MD, FACS

Surgeon, Orthopaedic Service

Stephen McDermott Chair in Surgery, Memorial Sloan Kettering Cancer Center

KATHERINE A. JANEWAY, MD, MMSC

Associate Professor of Pediatrics, Harvard Medical School

Senior Physician, Dana-Farber / Boston Children's Cancer and Blood Disorders Center

Director, Clinical Genomics, Dana-Farber Cancer Institute

MATT ALLEN

OsteoSibling

Aspiring Law Student

Client Advocate at the Delaware Office of Defense Services

MATTEO TRUCCO, MD

Director, Children's Cancer Innovative Therapy Program

Associate Professor of Pediatrics, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University

PETER ANDERSON MD, PH.D

Board Member, MIB Agents, Emeritus

RUSSELL PENZER

Dad to OsteoWarrior Max

Attorney

SHERRICK MURDOFF

Dad to Charlotte who battled osteosarcoma

Investor and M&A Advisor

SCIENTIFIC ADVISORY BOARD

ALANNA J. CHURCH, MD

Associate Director, Laboratory for Molecular Pediatric Pathology (LaMPP)
Staff Pathologist, Boston Children's Hospital
Assistant Professor of Pathology, Harvard Medical School

ALEX Y. HUANG, MD, PhD

Theresa G. & Stuart F. Kline Family Foundation Chair in Pediatric Oncology
Senior Attending Physician, Pediatric Hematology-Oncology
Director, Center for Pediatric Immunotherapy at Rainbow, Angie Fowler AYA Cancer Institute, UH Rainbow Babies & Children's Hospital
Professor of Pediatrics, Pathology, Biomedical Engineering and General Medical Sciences
Director, Medical Scientist Training Program, Case Western Reserve University School of Medicine
Co-leader, Immune Oncology Program, Case Comprehensive Cancer Center

DAMON REED, MD

Division Head, Pediatric Solid Tumors
Chief, Pediatric Sarcoma Service
Memorial Sloan Kettering Cancer Center

J. ANDY LIVINGSTON, MD, MS

Associate Professor, Department of Sarcoma Medical Oncology, Division of Cancer Medicine
Associate Professor, Department of Pediatrics Patient Care, Division of Pediatrics
Co-director, MD Anderson Adolescent and Young Adult (AYA) oncology program, The University of Texas MD Anderson Cancer Center, Houston, TX

JOHN H. HEALEY, MD, FACS

Board Member, MIB Agents
Surgeon, Orthopaedic Service
Stephen McDermott Chair in Surgery, Memorial Sloan Kettering Cancer Center

NICOLA MASON, BVETMED, PhD, DACVIM

The Paul A. James and Charles A. Gilmore Endowed Chair Professorship within the Department of Clinical Sciences and Advanced Medicine
Professor of Medicine & Pathobiology, University of Pennsylvania School of Veterinary Medicine

NICOLAS GARNIER, PhD

Chief Patient Officer, Servier

KATHERINE A. JANEWAY, MD, MMSC

Board Member, MIB Agents
Associate Professor of Pediatrics, Harvard Medical School
Senior Physician, Dana-Farber / Boston Children's Cancer and Blood Disorders Center
Director, Clinical Genomics, Dana-Farber Cancer Institute

MATTEO TRUCCO, MD

Director, Children's Cancer Innovative Therapy Program, Cleveland Clinic Children's
Associate Professor of Pediatrics, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University

PETER ANDERSON, MD, PhD

Board Member, MIB Agents, Emeritus

RAMY IBRAHIM, MD

Chief Medical and Strategy Officer, Georgiamune
Board Member, Cancer Help Desk
Member, Board of Directors, Parker Institute for Cancer Immunotherapy
Clinical Consultant, Altos Labs

ROSANDRA N. KAPLAN, MD

Senior Investigator, Pediatric Oncology Branch, National Cancer Institute/Center for Cancer Research

JUNIOR ADVISORY BOARD



KARA SKRUBIS

ITHACA, NY

Junior Advisory Board
Manager 2024, 2025

Junior Advisory Board
President 2022

Junior Advisory Board
Member 2021, 2023

Social Media Manager 2023,
2024, 2025

I am MIB Agents' Social Media and Junior Advisory Board Manager. I was diagnosed with osteosarcoma in January of 2020. I underwent 9 months of chemotherapy, a left above-the-knee amputation, and 8 months of immunotherapy. I then went on to serve on the MIB Agents JAB for three years, being the president in 2022, and then to become employed. I take pride in all that MIB Agents does for the community, and our work to Make It Better!



**SAMANTHA (SAMMY)
ULLOA**

VICTORVILLE, CA

Junior Advisory Board
President 2024, 2025

Junior Advisory Board
Member 2024

Hi all! My name is Sammy Ulloa, I am a 22 year old OsteoWarrior and I live in Southern California. Prior to my diagnosis, I was a Division 1 cross country and track athlete at Saint Mary's College of CA. I was diagnosed with osteosarcoma in my right proximal tibia at the age of 19 in August of 2022. I underwent 9 months of chemotherapy and a limb salvage surgery which left me with an internal prosthetic in my right leg. I completed treatment in May of 2023 and I have been in complete remission ever since. In my free time outside of my studies, I enjoy reading, spending time with family and friends, co-hosting MIB's AYA osTEAo podcast, and serving as the President of the 2025 MIB Junior Advisory Board.



MACKENZIE MADDRY

BELLA VISTA, AR

Junior Advisory Board Vice
President 2025

Junior Advisory Board
Member 2024

Hello my name is Mackenzie Maddry, I am an 18 year old senior in high school and I am the Vice President of the MIB Junior Advisory Board 2025. I live in Northwest Arkansas, and I was diagnosed with osteosarcoma in 2020 in my left femur at the age of 14. I had 9 months of MAP with a limb salvage surgery half way through and a cadaver bone was placed. That surgery lead to an infection a year after treatment and I had to have all hardware and the cadaver bone removed and replaced. The replacement took 3 surgeries, the last one sent me into heart failure. I was in the hospital for 3.5 months, and I received a LVAD Heartmate3 to pump my heart for me until transplant. I had a heart pump for 1.5 years before receiving a heart transplant in June 2024 and during that time also had two more surgeries and now have a metal rod in my leg. This is my second year as a Junior Advisory Board member and I am excited to see what this year has in store!



ALEJANDRO LOPEZ

SAN ANTONIO, TX

Junior Advisory Board
Member 2025

My name is Alejandro Lopez, I am a 22 year old OsteoWarrior and I live in South Texas. I was diagnosed with osteosarcoma in my left ankle 10 days after my 21st birthday in November of 2023. I underwent chemotherapy and a left below the knee amputation, I just recently got my prosthetic. I completed my chemotherapy in October of 2024, and have been NED since. I love spending time with God, fishing, being with family and friends, golfing, serving as a leader for my church and I co-run The Vasquez Sarcoma Foundation in supporting patients and their families in my home town of San Antonio, Texas.



ALLISEN RAMBUR
HUMBLE, TX

**Junior Advisory Board
Member 2023, 2024, 2025**

My name is Allisen Rambur, I am 17 years old and from Houston TX. I was diagnosed with osteosarcoma in my left femur at the age of 12 in November of 2019. I completed chemotherapy, radiation, and underwent limb salvage surgery. I have been in remission since September of 2020!! I enjoy listening to music, spending time with friends and family (and my cats!) and traveling and exploring new places!



ANDREW BISAGA
SAINT JOHN, IN

**Junior Advisory Board
Member 2020, 2022,
2023, 2024, 2025**

**Junior Advisory Board Vice
President 2021**

My name is Andrew Bisaga, and I am a 19-year-old OsteoWarrior. In late 2017, I was diagnosed with osteosarcoma in my right proximal femur, undergoing MAP chemotherapy and a limb salvage surgery. I was declared NED in early 2018 and have been since. I'm currently a sophomore at Creighton University studying biology, but in my free time I like to bake and play guitar.



**ANNE-KATRIN
URZYNICOK**
ABINGDON, MD

**Junior Advisory Board
Member 2025**

I am Anne-Katrin Urzynicok, I am 19 and the sibling of an OsteoWarrior Nicholas from Maryland. At 11 years old, Nicholas was diagnosed with osteosarcoma in both knees. In 2018. He went through a double limb sparing surgery and chemotherapy, and he has been in and out of treatment ever since with multiple relapses. I am studying biomedical engineering at the University of Michigan and hope to have a career in pediatric cancer research. In my free time, I enjoy movies, painting, and spending time with my family, friends, and dogs.



CAMILLE BRADY
WARREN, NJ

**Junior Advisory Board Member
2025**

Hi! My name is Camille Brady (22), and I'm an OsteoWarrior from New Jersey. I was first diagnosed with Ewing's sarcoma at 12-years-old, and remained in remission for five years before I was diagnosed with radiation-induced osteosarcoma during my senior year of high school. In addition to undergoing chemotherapy for the second time, I also underwent an extremely invasive surgery, where I received a total (left) hip replacement, as well as a pelvic reconstruction. This surgery impacted my motor function in my left leg, so I now use a crutch to walk and wear a brace to mediate my foot drop. While I'm not sure if I'll ever ditch the crutch, it doesn't slow me down — I love traveling the world, going to concerts, and walking countless blocks through New York City with my best friends. When I'm not on my feet, you'll often find me watching true crime documentaries or teaching myself how to crochet. I'm currently finishing my senior year at Cornell University and plan to move to Washington, D.C. after graduation. I'm incredibly honored to serve on MIB Agents' JAB '25 and give back to this amazing community!

JUNIOR ADVISORY BOARD



DANIEL SAPTARI
LEXINGTON, MA

Junior Advisory Board
Member 2023, 2024, 2025

My name is Daniel Saptari, and I am an 18 year old OsteoWarrior from Massachusetts! I was diagnosed with osteosarcoma in my left distal femur in July 2020. I then underwent over a year of chemotherapy and immunotherapy and a bone-growth limb-salvage procedure, and I have been NED ever since. In July 2023, I had a rotationplasty amputation. In my free time, I love to design and build devices for science competitions, fly model planes, and spend time with family and friends. I am grateful for this opportunity to be able to serve on MIB's Junior Advisory Board.



ELISE ROBINSON
THE WOODLANDS, TX

Junior Advisory Board
Member 2021, 2022, 2023,
2024, 2025

Hi I'm Elise Robinson. I am 18 from Houston Texas and 10 years in remission from osteosarcoma with a rotationplasty. I am currently a freshman at Texas A&M University for nursing. I am also an Ambassador Agent for MIB. In my free time I enjoy painting my own nail art and this will be my fifth year on MIB's Junior Advisory Board.



EVAN SAPTARI
LEXINGTON, MA

Junior Advisory Board
Member 2025


My name is Evan Saptari. I am a 16 year old OsteoSibling and a junior at Lexington High School in Massachusetts. My brother was diagnosed with osteosarcoma in his left distal femur during the COVID years of 2020. He went through chemotherapy and immunotherapy for over a year, working towards a bone-growth limb-salvage series of procedures. After complications, he underwent a rotationplasty amputation in July of 2023. In my free time I play tennis both for my high school team and recreationally, play guitar for my church, I enjoy learning new skills, and I love spending time with my friends and family. I am very grateful for this opportunity to serve on the MIB Junior Advisory Board, and I am excited to see what we can do!



GILLIAN BOMI OKIMOTO
NEW YORK, NY

Junior Advisory Board
Member 2023, 2024, 2025

My name is Gillian Bomi Okimoto, I was diagnosed with osteosarcoma in 2017, and went through nine months of chemotherapy and nine surgeries over the next five years. I went through a process called distraction osteogenesis, a procedure to regrow my femur. I currently college at Rhode Island School of Design and Brown University. I enjoy watching many sports, and I love baking and reading.



INAAYA SHARIQ

NAPERVILLE, IL

**Junior Advisory Board
Member 2025**

My name is Inaaya Shariq, I am a 16 year old 2x OsteoSurvivor and I live in Chicago. I was diagnosed with osteosarcoma when I was 11 in my right thigh during October 2020. I went through 10 months of chemotherapy and a limb salvage surgery, so I had an internal prosthesis in my right thigh plus a knee replacement. I was cancer-free for 2 years, until November 2023 in freshman year when I was re-diagnosed with osteosarcoma in my right leg again when I was 14. I went through 6 more months of chemotherapy until April 2024 when I had to amputate my entire right leg with a hipdisarticulation surgery when I was 15. In my free time, I enjoy reading, writing, swimming, watching movies, and spending time with friends and family.




JACOB KNUDSEN

WINDSOR, CA

Junior Advisory Board

Member 2025

My name is Jacob Knudsen, I am a 17 year old OsteoWarrior and I live in Northern California. I was diagnosed with osteosarcoma in my right femur at 12 years old in September 2019. I underwent chemotherapy and a limb salvage surgery, so now I have an internal prosthetic and knee replacement in my right leg. I completed treatment in May 2020, then relapsed in my lung in May 2021. Since then I have been able to get to NED, but not for long periods of time. I have had 4 recurrences total including the worst one in February 2023, when my recurrence included a nodule in my lung, one in my lymph node, and one in my kidney. I've been on several treatment regimens including two clinical trials. I'm currently on a clinical trial and am two months NED. My hobbies include sports, working out, hanging out with friends and family, traveling and trying to spread kindness, and awareness for childhood cancer.




KEELY TAMAYOSE

PEARL CITY, HI

Junior Advisory Board

Member 2025

Aloha everyone! My name is Keely Tamayose and I am an OsteoSibling. I am a Freshman at Pearl City High School in Pearl City, Hawaii. My sister Ally was diagnosed with osteosarcoma in 2018 and passed away in 2023. I loved helping my sister with all the fundraisers she did for MIB and I hope to help continue her legacy. I love playing soccer, being apart of student council and spending time with my family and friends.



LINCOLN ZICK

BURBANK, CA

**Junior Advisory Board
Member 2025**

My name is Lincoln Zick and I am a 16 year old OsteoWarrior survivor living in Los Angeles. I was diagnosed twice, once in the right tibia, and then in the right humerus. I have always had an active lifestyle and even after my treatments and surgeries, I still participate in my high school's swimming and golfing teams. Currently in remission, I am excited to serve as a member of the JAB!

JUNIOR ADVISORY BOARD



LUKE CARTER
MCLEAN, VA

Junior Advisory Board
Member 2024, 2025

My name is Luke Carter, and throughout my life, I've heard stories of my uncle Scott who passed away from osteosarcoma when he was my age. His legacy and dream to generate money and find a cure for cancer live on in my family and my own life. I'm a high school junior and love to run, golf, make art, and play piano.

MATTHEW CEELEN
MEQUON, WI

Junior Advisory Board
Member 2024, 2025

My name is Matthew Ceelen and I was diagnosed with high grade osteosarcoma in August 2017. Over the following year I was treated with the MAP chemotherapy protocol and Mifamurtide immunotherapy. Additionally, over the next several years, I underwent multiple limb salvage surgeries and revisions. Since officially completing my chemotherapy/immunotherapy treatments in August of 2018, I have remained NED. I am currently a Senior at the University of Wisconsin-Madison studying Biomedical Engineering with the hopes of continuing my medical journey in medical school, enroute to becoming an orthopedic oncologist. In my spare time, I enjoy running, reading about history, serving on the MIB Agents Junior Advisory Board, and joining osTEAo podcasts to display my love for tea and discuss with my friends about our shared experiences.

MAX PENZER
MELVILLE, NY

Junior Advisory Board
Member 2022, 2023, 2025
Junior Advisory Board Vice
President 2024

Hi, I'm Max, and I'm from Long Island, NY. I'm currently studying chemistry at Tufts University in Boston, MA. I was diagnosed with osteosarcoma in my right distal femur when I was ten years old, in 2015. I was treated at NewYork-Presbyterian and am almost 9 years NED. I'm an MIB Ambassador Agent, and this is my fourth year on the MIB JAB. In my free time, I enjoy crocheting and watching new TV shows—my favorites are The White Lotus and Parks and Recreation.



MICHAELA BOGON
COLLINGSWOOD, NJ

Junior Advisory Board
Member 2025


Hello! My name is Michaela Bogon, I am a 19 year old OsteoWarrior living in South Jersey. I was diagnosed with osteosarcoma to my right humerus with bilateral lung metastasis in December of 2022, right at the beginning of my senior year of high school. I completed a 9 month course of standard MAP chemotherapy, during which I underwent limb salvage surgery with cadaver bone transplant and right shoulder prosthesis. During treatment, I also underwent 3 thoracotomies (lung surgeries) with the last showing micro-tumors on pathology. This means my cancer is considered non-curative and ongoing treatment has consisted of oral chemo, TKI drugs, and 3 different kinds of radiation to treat new metastatic disease to the lungs, leg, and brain. I love spending time with family and friends, cuddling with my Boston Terrier, Violet, spending time at the beach, building legos, and watching cooking shows. I am very much looking forward to serving on the MIB's Junior Advisory Board.



MIKAELA NAYLON
PUEBLO, CO

**Junior Advisory Board
Member 2025**

My name is Mikaela Naylor, and I'm 15 years old. I live in Southern Colorado, and I was diagnosed with osteosarcoma in July 2020 at 10 years old. My tumor was in my left ankle and spread to both of my lungs. I've done numerous treatments in Children's Hospital in Aurora, MD Anderson, and the Cleveland Clinic. I got my leg amputated below the knee in October 2020 and had many lung surgeries after that. I've always been involved in advocacy; I've been on radio shows and local TV news anchors advocating for childhood cancer! I love hockey, cats, snowboarding, F1 and tennis!



MOLLY PENZER
MELVILLE, NY

**Junior Advisory Board
Member 2024, 2025**

Hi, I am Molly Penzer. I am seventeen years old and planning to attend the University at Buffalo this fall! This is my second year on the MIB JAB, but my connection to this organization goes back many years. Childhood cancer, especially rarer types, is often overlooked in society, and when my brother was diagnosed with osteosarcoma at ten years old, my family had no guidance on how to emotionally handle the extremely serious situation. Then, we discovered MIB. MIB has been a comforting, supportive and educational resource for my entire family ever since. Thankfully, my brother Max is now NED and serves with me on the JAB. Max and I continue to expand our knowledge of the disease and its effects, as well as possible treatments alongside our JAB peers.



SEBASTIAN WANG
KINGWOOD, TX

**Junior Advisory Board
Member 2025**

My name is Sebastian Wang. I am 15 years old living in Houston, Texas. My brother Jaden was diagnosed on April 26, 2021 with osteosarcoma in his right humerus. His brave, 3.5 year fight with osteosarcoma taught me many things about the disease, about love, and the importance of spending time with family. In my free time, I enjoy playing chess, piano, and basketball. I also enjoy hanging out with friends and playing outside.



SLOANE DYER
ATLANTA, GA

**Junior Advisory Board Member
2020, 2023, 2024, 2025**

My name is Sloane Dyer. I'm 20 years old from Chicago and Atlanta. I was diagnosed with osteosarcoma in my distal right femur in December, 2016 when I was twelve. I went through full MAP protocol and had an initial limb salvage of my right femur and knee. I spent 6 years with my limb salvage and then electively chose amputation to address pain issues. I am now 7 years no evidence of disease and going to college in Texas getting a degree in vocal jazz studies!

JUNIOR ADVISORY BOARD



SONA KOCINSKY
TRUMBULL, CT

Junior Advisory Board
Member 2024, 2025


My name is Sona Kocinsky. I am originally from Connecticut and currently live in the Boston area. I was diagnosed with osteosarcoma in my scapula in late 2019 at age 16, for which I underwent chemotherapy and surgery during my junior and senior years of high school. Now 21, I am almost five years cancer-free and a senior at Tufts University, where I study biology and physics. My cancer experience has played a key role in my aspirations for a career in medicine, and in the fall of 2025, I will be starting medical school. Beyond academics, I enjoy running, rock climbing, and listening to music. I am so excited to be returning for my second year on MIB Agents' Junior Advisory Board alongside an incredible group of advocates.



TE'VON BERRY JR.
ORANGE PARK, FL

Junior Advisory Board
Member 2025

My name is Te'von Berry Jr and I am a 17 year old high school senior. I reside in Florida but I was born in Baltimore, MD. I was diagnosed with osteosarcoma in my right femur on August 28, 2023 just 2 weeks before my 16th birthday. I completed 9 months of in-patient chemotherapy and had limb salvage surgery. I completed my in-patient chemotherapy on May 6, 2024. Unfortunately, on October 4, 2024 I found out that my cancer returned in my right shoulder, 7th rib and in my lungs. Currently my treatment plan is taking oral chemotherapy pills everyday. I'm scheduled to have a reverse shoulder replacement on February 26, 2025 and the areas in my lungs and rib are now stable and shrinking. Above everything I love Jesus Christ and my faith is very important to me. I enjoy spending time with my family, playing video games, going to church and working my part-time job. My dream is to become a Residential Architect with hopes of attending a 4 year HBCU Fall 2025.



WALKER SMALLWOOD
VERONA, KY

Junior Advisory Board
Member 2022, 2024, 2025

Junior Advisory Board Vice President 2023

My name is Walker Smallwood, I am a 21-year-old OsteoWarrior and am from Northern Kentucky but currently live in Lexington Kentucky while I am finishing up my senior year of undergrad. Since diagnosis in 2018, I underwent typical MAP therapy and opted for a limb salvage surgery when they removed the primary tumor from my left proximal tibia. I was NED until the summer of 2020 when quarterly scans revealed a cancerous nodule in my left lung. Following the resection of that nodule I have thankfully been NED since. Outside of class I enjoy hanging out with family friends, being active, and cheering on the Kentucky Wildcats. This is now my 4th year on the Junior Advisory Board, and I can't wait to see what this year brings for the JAB and MIB as a whole.

ABOUT MIB AGENTS FAMILY FUNDS

WHAT IS A FAMILY FUND?

Each Family Fund honors a child who has experienced or is in treatment for osteosarcoma, or the memory of a child who has passed from osteosarcoma. Their efforts fund desperately needed osteosarcoma research, educational resources, and programs that support kids and families in treatment.

HOW DOES MIB AGENTS HELP ME HONOR MY LOVED ONE?

Every Family Fund honoree has a personal page on our website with customized content for each honoree's story. We share those stories on our website, twice a year on social media, at our FACTOR conference, and during other MIB events throughout the year.

Family Funds have an opportunity to co-brand Outsmarting Osteosarcoma research grants and provide valuable patient perspective during our grant review process. Thanks to MIB Family Funds, MIB Agents has supported \$1.9 million in research grants since 2017.

HOW DO I SET UP MY FAMILY FUND?

It is easy to open your Family Fund. Visit <https://www.mibagents.org/about-family-funds> to learn more about how to establish your Family Fund. You may also email Isabel Wolf, Director of Programs, Isabel@MIBagents.org or speak with one of our Family Fund Advisory Council members: Nichole Beutlich, Linda Chelsky, Bronwen Greene, Roberta Lehrman, or Karen Marsh.

Family Funds are an essential part of the mission of MIB Agents to Making It Better for those facing osteosarcoma.

Please consider being part of this important program.



WE PERSEVERE

MIB AGENTS FAMILY FUNDS

In honor and memory of their children, Family Funds raise money to Make It Better for kids and young adults with osteosarcoma. Their efforts fund programs that support kids in treatment and bereaved families, educational resources, and desperately needed osteosarcoma research. Family Funds have an opportunity to co-brand research grants and provide valuable patient perspective during our grant review process.

AIDEN

OsteoWarrior



ALEX

OsteoAngel



ALLISEN

OsteoWarrior



ANDREW

OsteoWarrior



ANNALEIGH

OsteoAngel



ARNAV

OsteoAngel



AVA

OsteoWarrior



AVERY

OsteoAngel



BRENTON

OsteoAngel



BRIANA

OsteoAngel



BROOKE

OsteoAngel



BROOKLYN

OsteoAngel



BUDDY

OsteoWarrior



CARSON

OsteoAngel



CHARLOTTE

OsteoAngel



CHRIS

OsteoAngel



CLAYTON

OsteoAngel



DANIEL

OsteoWarrior



DYLAN

OsteoAngel



EDWARD

OsteoAngel



ELI

OsteoAngel



ELLA

OsteoAngel



GAVIN

OsteoAngel



GILLIAN

OsteoWarrior



IAN
OsteoAngel



ISAAC
OsteoAngel



JACK
OsteoWarrior



JADEN
OsteoAngel



KRYSTY
OsteoAngel



KYLE
OsteoAngel



LEAH
OsteoAngel



MARISSA
OsteoAngel



MATTHEW
OsteoAngel



MEGAN
OsteoAngel



MIA
OsteoAngel



MICHAEL
OsteoAngel



MOHAN
OsteoAngel



NATALIE
OsteoAngel



NICHOLAS
OsteoAngel



NORAH
OsteoAngel



PATRICK
OsteoAngel



PENELOPE
OsteoAngel



REESE
OsteoAngel




RYAN K
OsteoWarrior



RYAN T
OsteoAngel



SETH
OsteoAngel



SLOANE
OsteoWarrior



SYDNEY
OsteoAngel



TYLER M
OsteoAngel



TYLER Y
OsteoAngel



VICTORIA
OsteoAngel



ZACHARY
OsteoAngel



FAMILY FUND ADVISORY COUNCIL

The Family Fund Advisory Council are experienced Family Fund Members who are available to share and discuss Family Funds with OsteoWarrior and OsteoAngel Families.



NICHOLE BEUTLICH

I am OsteoMom to Warrior Aiden, who was diagnosed with Osteosarcoma in 2021. My family and I live in San Diego, California. We are so thankful to be part of the MIB community and enjoy being Writer Agents for Warrior Mail. Having a Family Fund has given our family the opportunity to help Make It Better by furthering research and patient support programs.



LINDA CHELSKY

I am an OsteoMom to OsteoAngel Leah, and our family is from Portland, Oregon. Leah's 3 1/2 year osteosarcoma journey started when she was 21 years old and a recent grad from University of Oregon. Family Funds at MIB Agents has allowed us to continue Leah's fighting spirit through osteosarcoma research and other family support programs.



BRONWEN GREENE

I am mom to OsteoAngel, Ian, who passed away from osteosarcoma in May of 2020 after being diagnosed only 6 months prior. We started our Family Fund to honor Ian's memory by fighting on behalf of every other OS patient and their families. While our primary goal is to fund research into new and better treatments for OS (and a cure!), we have seen how MIB Agents' programs also provide support and encouragement for OsteoWarriors during treatment and into survivorship, as well as support for other bereaved families like us. I live in Greenville, SC, with my husband, two teenage daughters, and our sweet golden retriever, Tucker.



ROBERTA LEHRMAN

My name is Roberta Lehrman and I live in Delray Beach, Florida. Eight years ago my son, Matthew, passed away from osteosarcoma at the age of 24. From his hospital bed, Matthew raised money that was donated to MIB Agents, initiating our Family Fund. It is my honor to be a member of MIB Agents' Family Fund Advisory Council and to be a part of their mission to support children and families suffering from this devastating illness.







KAREN MARSH

I am mom to OsteoAngel Victoria, who was diagnosed at age 13. I found MIB Agents through another Delaware family whose son had just received an MIB mission. We were fairly early in our journey and needed resources. I reached out and, within a day, Ann called me—and our family has been involved with MIB ever since. I attended the first FACTOR conference thanks to a generous sponsorship, and I will be forever grateful. We immediately started a Family Fund through MIB, which our friends and family continue to support to this day. Knowing we are supporting state-of-the-art research—and that we, as Family Fund holders, have a say in how the money is allocated—is unprecedented in any nonprofit we've supported before. I look forward to becoming more involved as we continue to Make It Better.

FACTOR TRAVEL AWARDS

FACTOR Travel Awards are supported by MIB Agents Family Funds. Their dedication to Making It Better and fostering collaboration and education in the scientific community helps us assemble passionate and engaged scientists from around the US and world at FACTOR.

MIB Agents Family Funds also generously support the attendance of OsteoWarrior families who have been nominated by their care teams, allowing them to experience FACTOR.



WE PERSEVERE



**IT'S NOT MY MONEY, IT'S GOD'S
MONEY. LET IT HELP WITH WHATEVER
LITTLE BIT OF GOD'S WORK IT CAN.**

— NELDA WILKOMIRSKI



WE PERSEVERE



Above: Nelda Wilkomirski and her beloved grandson, Devin van Hoven, at the 2020 FACTOR Conference in Phoenix. In the summer of 2024, Mrs. Wilkomirski passed away, leaving MIB Agents a generous gift in honor of Devin's fight against humoral osteosarcoma and in hope for progress in treating this formidable foe. We are profoundly grateful for her enduring contribution to our community.

FACTOR VOLUNTEER AGENTS

BENTLEY DYER

HQ Lead Gamer Agent

BURT TOMA

IT & Event Support

JACK SUTPHIN

Event Set-Up

JOHN GRAHAM

Operations

JUDY KEOSAKSITH

Registration and Event Support

KYLE OKIMOTO

Floor Manager

LESLIE PETERSON

Wellness Contributor

LINDA KENNINGTON

Photography, Luminaria, Ribbons

MAEVE SMART

OsteoWarriors HQ Co-Chief

MARK ATKINS

Floral & Events

MATT ALLEN

DJ for FACTOR Formal

MATTEO TRUCCO, MD

Co-Chair

MICHELLE PRESTON

OsteoWarriors HQ Co-Chief

RANDI BARTLES

Registration

REBECCA ROGERS

Onsite Welcome & Registration

SARAH NICKELS

Registration & Shipping

SASSY PICKARD & TERRI COOK

FSRS Rabbit Rescue & Sanctuary

SEAN BROSNAN

HQ Lead Gamer Agent

SHANNAH BLAIN

Floral & Events

TEDD KAPINOS

Floral & Events, Wellness Contributor

VENDOR PARTNERS

DONNY MILLER & TEAM / 730 EDDY

Location Video Videography

ETHAN ENGESETH

HQ Photography

JUDY KEOSAKSITH

Printed Program Design

LORI KRAUSE / HAND HOLDERS LLC

Healing Hearts Facilitator

NATIONAL ABILITY CENTER

Docs vs. Warriors Challenge & Caretaker of
FACTOR Shipments



SERB is Proud to Sponsor MIB Agents

Collaborating to Make It Better

for the pediatric osteosarcoma community
of patients, caregivers, doctors, and researchers

